ID Species ncRNA ncRNA type Environmental factor (EF) Phenotype Sample Condition of EF Evidence PubMed ID 1 Mouse RNCR3 lncRNA high glucose (HG) diabetic retinopathy (DR) RF/6A cells high glucose stress upregulated 27876564 2 Mouse 1110038B12Rik lncRNA X rays radiation-induced injury blood X rays treatment downregulated 29309266 3 Mouse 1700009J07Rik lncRNA high fat diet (HFD) male infertility C57bl/6J mice high fat diet (HFD) feed dysregulated 28599310 4 Mouse 1700020I14Rik lncRNA hypoxia/reoxygenation (H/R) myocardial injury HL-1 cells hypoxia/reoxygenation (H/R) treatment 1700020I14Rik/miR-297a/CGRP axis suppressed myocardial cell apoptosis in myocardial I/R injury. 32298875 5 Mouse 1700026D11Rik lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment upregulated 32246647 6 Mouse 1700091H14Rik lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment downregulated 32246647 7 Mouse 1810034E14Rik lncRNA lipopolysaccharide (LPS) ischemic stroke (IS) primary microglial cells lipopolysaccharide (LPS) treatment downregulated 30961627 8 Mouse 1810034E14Rik lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) primary microglial cells oxygen-glucose deprivation treatment downregulated 30961627 9 Mouse 2310069B03Rik lncRNA cold obesity white adipose tissues cold treatment Cold exposure increased both lncRNA 2310069B03Rik and Ucp1 expression in inguinal white adipose tissue (iWAT). 31601163 10 Mouse 2610035D17Rik lncRNA rosiglitazone diabetic nephropathy (DN) kidney tissues rosiglitazone treatment upregulated 32025515 11 Mouse 2700086A05Rik lncRNA paraquat (PQ) idiopathic pulmonary fibrosis (IPF) alveolar epithelial cells paraquat (PQ) treatment upregulated 26824344 12 Mouse 2810403D21Rik lncRNA H2O2 acute myocardial infarction (AMI) Neonatal mice cardiomyocytes (NMCMs) hydrogen peroxid (H2O2) treatment "forced expression of 2810403D21Rik/Mirf downregulated Mir26a to inhibit autophagy. In contrast, loss of 2810403D21Rik/Mirf resulted in upregulation of Mir26a to promote autophagy and alleviate cardiac injury, which in turn improved cardiac function in MI mice." 31512556 13 Mouse 2900052N01Rik lncRNA lipopolysaccharide (LPS) inflammation B lymphocytes lipopolysaccharide (LPS) treatment lnc-290 was highly expressed in B cells stimulated by LPS 33773377 14 Mouse 4930556M19Rik lncRNA high glucose (HG) diabetic nephropathy (DN) podocytes high glucose (HG) treatment 4930556M19Rik overexpression slowed HG-induced podocyte injury by downregulating miR-27a-3p and upregulating TIMP3. 32896839 15 Mouse 4930597A21Rik lncRNA dexamethasone (DEX) asthma lung tissues dexamethasone (Dex) treatment 4930597A21Rik was upregulated in the Dex group compared with that in the Model group. 32222886 16 Mouse 6430584L05Rik lncRNA "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)" rheumatoid arthritis (RA) TM3 Leydig cells "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment" upregulated 33360214 17 Mouse 9030404E10Rik lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment upregulated 32246647 18 Mouse A_30_P01018532 lncRNA albizia julibrissin (AJSAF) cell function RAW264.7 macrophages albizia julibrissin (AJSAF) treatment upregulated 31678866 19 Mouse A330023F24Rik lncRNA vorinostat (SAHA) atherosclerosis (AS) aortic tissues vorinostat treatment upregulated 30284929 20 Mouse AA089093 lncRNA X-rays radiation-induced injury mouse thymocytes X-ray irradiation upregulated 27864278 21 Mouse AA591058 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment AA591058 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 22 Mouse AA591058 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment downregulated 29115403 23 Mouse AA591058 lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment AA591058 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 24 Mouse ACART lncRNA H2O2 ischemia/reperfusion (I/R) injury Neonatal mouse ventricular cardiomyocytes (NMVCs) H2O2 treatment LncRNA ACART protects cardiomyocytes from apoptosis by activating PPAR-¦Ã/Bcl-2 pathway 31749326 25 Mouse ACART lncRNA H2O2 myocardial ischemia/reperfusion (I/R) injury (MIRI) primary cultured cardiomyocytes H2O2 treatment downregulated 31749326 26 Mouse ACOD1 lncRNA esicular stomatitis virus (VSV) esicular stomatitis virus (VSV) infection macrophages stimulated with VSV for 12 hours upregulated 29074580 27 Mouse AIR lncRNA "diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC)" liver preneoplastic foci and tumors mice liver cells "Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC) treatment" upregulated 19362547 28 Mouse AK006025 lncRNA human immunodeficiency virus (HIV)-1 Nef HIV-associated neurocognitive disorders (HAND) primary mouse astrocytes Human immunodeficiency virus (HIV)-1 Nef treatment upregulated 30382871 29 Mouse AK009366 lncRNA pressure overload heart failure (HF) heart sissues pressure overload treatment upregulated 33224746 30 Mouse AK020546 lncRNA H2O2 cardiomyocyte autophagy primary cardiomyocytes H2O2 treatment AK020546 was decreased upon H2O2 treatment 29295976 31 Mouse AK028245 lncRNA cyclophosphamide (CP) ircadian rhythmicity mouse cyclophosphamide (CP) treatment downregulated 32748687 32 Mouse AK028245 lncRNA lipopolysaccharide (LPS) ircadian rhythmicity mouse lipopolysaccharide (LPS) treatment downregulated 32748687 33 Mouse AK038897 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) neuro-2A (N2a) neuroblastoma cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 30703362 34 Mouse AK038898 lncRNA radiation radiation-induced intestinal injury intestinal tissues radiation treatment downregulated 30324649 35 Mouse AK039862 lncRNA paraquat (PQ) parkinson's disease (PD) BV2 cells paraquat (PQ) treatment upregulated 33120262 36 Mouse AK039862 lncRNA paraquat (PQ) parkinson's disease (PD) BV2 cells paraquat (PQ) treatment PQ-induced low expression of AK039862 rescued microglia proliferation and migration inhibition via the AK039862/Pafah1b1/Foxa1 pathway. 33120262 37 Mouse AK043271 lncRNA X-rays radiation-induced injury mouse thymocytes X-ray irradiation downregulated 27864278 38 Mouse AK045171 lncRNA angiotensin II (Ang II) cardiac hypertrophy Neonatal mouse cardiomyocytes and cardiac fibroblasts angiotensin II (Ang II) treatment Overexpression of AK045171 attenuated cardiac hypertrophy both in vitro and in vivo. 32087602 39 Mouse AK054386 lncRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) BNL-CL2 hypoxia induce upregulated 31827704 40 Mouse AK077216 lncRNA macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL) osteoclastogenesis RAW 264.7 cells and Bone marrow and spleen derived monocytes/macrophages macrophage colony©\stimulating factor (M©\CSF) and receptor activator of nuclear factor ¦ÊB ligand (RANKL) treatment upregulated 30132869 41 Mouse AK080622 lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment decreased 25827714 42 Mouse AK081017 lncRNA streptozocin (STZ) diabetic neuropathic pain (DNP) mouse brain tissues streptozotocin treatment dysregulated 30599267 43 Mouse AK081284 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) Cardiac fibroblasts (CFs) high glucose (HG) treatment The levels of long noncoding RNA-AK081284 were increased in the CFs treated with high glucose or IL-17. 29305939 44 Mouse AK081284 lncRNA IL-17 diabetic cardiomyopathy (DCM) Cardiac fibroblasts (CFs) IL-17 treatment IL-17 treatment increased the expression of AK081284 in CFs. 29305939 45 Mouse AK081284 lncRNA streptozocin (STZ) diabetic cardiomyopathy (DCM) cardiac tissues streptozocin (STZ) treatment upregulated 29305939 46 Mouse AK083162 lncRNA X-rays radiation-induced injury mouse thymocytes X-ray irradiation downregulated 27864278 47 Mouse AK083183 lncRNA radiation radiation-induced intestinal injury intestinal tissues radiation treatment downregulated 30324649 48 Mouse AK085865 lncRNA dermatophagoides farinae protein 1(Der f1) allergic asthma (AA) M2 macrophages Der f1 treatment upregulated 32247269 49 Mouse AK085865 lncRNA coxsackievirus B3 (CVB3) viral myocarditis (VM) M1 macrophages coxsackievirus B3 (CVB3) treatment upregulated 32220054 50 Mouse AK085865 lncRNA coxsackievirus B3 (CVB3) viral myocarditis (VM) heart sissues Coxsackievirus B3 (CVB3) infection downregulated 32668391 51 Mouse AK089579 lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment decreased 25827714 52 Mouse AK133602 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment AK133602 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 53 Mouse AK133602 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment downregulated 29115403 54 Mouse AK133602 lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment AK133602 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 55 Mouse AK142426 lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment upregulated 25827714 56 Mouse AK144841 lncRNA "promoter (7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA)" cutaneous squamous cell carcinoma (cSCC) cSCC and highly tumorigenic cells "DMBA,TPA treatment" upregulated 28596382 57 Mouse AK148321 lncRNA lipopolysaccharide (LPS) neuroinflammation BV2 cells lipopolysaccharide (LPS) treatment LPS treatment suppressed AK148321 expression in BV2 cells. 33301806 58 Mouse AK148321 lncRNA lipopolysaccharide (LPS) neuroinflammation BV2 cells lipopolysaccharide (LPS) treatment LPS treatment suppressed AK148321 expression in BV2 cells. Overexpression of AK148321 inhibited LPS-induced BV2 microglial cell activation and decreased the expression of inflammatory cytokine TNF-¦Á and IL-1¦Â. 33301806 59 Mouse AK149641 lncRNA ovalbumin (OVA) asthma lung tissues ovalbumin (OVA) treatment downregulated of lncRNA-AK149641 attenuated the airway inflammatory response in an OVA-induced asthma mouse model. 32929606 60 Mouse AK156531 lncRNA propofol (PPF) acute neurotoxicity hippocampus propofol treatment downregulated 30261491 61 Mouse AK157361 lncRNA radiation radiation-induced intestinal injury intestinal tissues radiation treatment upregulated 30324649 62 Mouse ANCR lncRNA ¦Â-glycerophosphate (¦Â-GP) arterial calcification vascular smooth muscle cells (VSMCs) ¦Â-glycerophosphate (¦Â-GP) treatment ANCR may inhibit the osteoblastic differentiation of VSMCs and attenuate mice arterial calcification through activating autophagy 31974677 63 Mouse ANRIL lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) kidney tissues lipopolysaccharide (LPS) treatment The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells 32069473 64 Mouse ANRIL lncRNA metformin (Met) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) Metformin treatment Metformin activates AMPK to suppress the formation of atherosclerotic plaque through upregulation of lncRNA-ANRIL. 33411680 65 Mouse ANRIL lncRNA high glucose (HG) diabetic nephropathy (DN) MPC5 cells high glucose (HG) treatment upregulated 32617859 66 Mouse ANRIL lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) N-2a cells oxygen and glucose deprivation treatment ANRIL protects N-2a cells against ischemia induced injury by elevated CAV-1 by competitively interacting with miR-199a-5p 31907708 67 Mouse ANRIL lncRNA ischemia type 2 diabetes mellitus (T2DM) peripheral venous blood ligation of the left anterior descending coronary artery treatment upregulated 31469688 68 Mouse ANRIL lncRNA streptozocin (STZ) wound healing granulation tissues streptozocin (STZ) treatment "ANRIL was downregulated, in the diabetic wound healing mouse model" 30565672 69 Mouse Arid2-IR lncRNA high fat diet (HFD) diabetic nephropathy (DN) mouse kidney tissues high fat diet (HFD) feed Arid2-IR was increased in mice with high-fat diet and streptozotocin-induced type 2 diabetes and in mouse mesangial cells cultured with high glucose to mimic diabetes 30462533 70 Mouse Arid2-IR lncRNA high fat diet (HFD) and streptozotocin (STZ) diabetic nephropathy (DN) kidney tissues high fat diet (HFD) and streptozotocin (STZ) treatment upregulated 30462533 71 Mouse Arid2-IR lncRNA high glucose (HG) diabetic nephropathy (DN) mouse mesangial cells high glucose (HG) treatment upregulated 30462533 72 Mouse Arid2-IR lncRNA high glucose (HG) diabetic nephropathy (DN) mouse mesangial cells high glucose treatment Arid2-IR was increased in mice with high-fat diet and streptozotocin-induced type 2 diabetes and in mouse mesangial cells cultured with high glucose to mimic diabetes 30462533 73 Mouse Arid2-IR lncRNA streptozocin (STZ) diabetic nephropathy (DN) mouse kidney tissues streptozotocin treatment Arid2-IR was increased in mice with high-fat diet and streptozotocin-induced type 2 diabetes and in mouse mesangial cells cultured with high glucose to mimic diabetes 30462533 74 Mouse ASIR lncRNA insulin cell metabolism mouse primary Adipocyte culture insulin treatment upregulated 30948776 75 Mouse AU015836 lncRNA glyoxylate kidney damage and kidney stones C57BL/6J mice glyoxylate upregulated 29160413 76 Mouse AU020206 lncRNA "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)" rheumatoid arthritis (RA) TM3 Leydig cells "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment" upregulated 33360214 77 Mouse AW112010 lncRNA H2O2 age-related hearing loss (AHL) HEI-OC1 Cells H2O2 treatment upregulated 31781342 78 Mouse B230206L02Rik lncRNA propofol (PPF) propofol-induced neurotoxicity hippocampus propofol treatment downregulated 29628875 79 Mouse BACE1AS lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment downregulated 32626785 80 Mouse Bace1-as lncRNA memantine Alzheimer's disease (AD) brain and blood tissues memantine treatment upregulated 32648077 81 Mouse BC049991 lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment decreased 25827714 82 Mouse BDNF-AS lncRNA hypoxia apoptosis C57BL/6J mice neonatal cardiomyocyte treat with either long (Hypoxia (L)) or short (Hypoxia (S)) H/R upregulated 28363791 83 Mouse Blnc1 lncRNA oxygen glucose deprivation (OGD) intracerebral haemorrhage (ICH) brain tissues oxygen and glucose deprivation (OGD) treatment "Blnc1 was upregulated in perihematomal edema, hematoma and microvessel in the brain of ICH mice" 33359247 84 Mouse Blnc1 lncRNA oxygen glucose deprivation (OGD) intracerebral haemorrhage (ICH) primary brain microvascular endothelial cells (BMVECs) oxygen and glucose deprivation (OGD) treatment upregulated 33359247 85 Mouse Blnc1 lncRNA high fat diet (HFD) mitochondrial function of white adipose tissue (WAT) 3T3-L1 pre-adipocytes high fat diet (HFD) feed Blnc1 Protects Against Diet-Induced Obesity by Promoting Mitochondrial Function in White Fat 32368112 86 Mouse Blnc1 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) liver tissues high fat diet (HFD) feed upregulated 30061575 87 Mouse Braveheart lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment upregulated 32626785 88 Mouse Bvht lncRNA hypoxia/reoxygenation (H/R) epithelial-mesenchymal transition (EMT) MSCs exposure to hypoxia (1% O2) and serum deprivation for 24 h upregulated 28095922 89 Mouse C0300307D09Rik lncRNA "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)" rheumatoid arthritis (RA) TM3 Leydig cells "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment" upregulated 33360214 90 Mouse C2dat2 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury Mouse N2a cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 33833132 91 Mouse CASC15 lncRNA angiotensin II (Ang II) cardiac hypertrophy cardiomyocyte angiotensin II (Ang II) treatment CASC15 expression was upregulated when cardiomyocytes were treated with Ang-II. 29966657 92 Mouse CASC2 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) lung tissues lipopolysaccharide (LPS) treatment downregulated 29492259 93 Mouse CASC2 lncRNA high glucose (HG) diabetic nephropathy (DN) mouse podocyte cells high glucose treatment downregulated 29890555 94 Mouse CCAT-1 lncRNA tumor necrosis factor alpha (TNF-¦Á) apoptosis Podocytes were isolated from mice tumor necrosis factor alpha (TNF-¦Á) treatment CCAT1 induction critically participated in apoptosis inhibition in podocytes through autophagy inhibition via increasing PI3K/Akt signaling 31468575 95 Mouse CCAT-1 lncRNA tumor necrosis factor alpha (TNF-¦Á) podocyte apoptosis Podocytes tumor necrosis factor alpha (TNF-¦Á) treatment CCAT1 induction critically participated in apoptosis inhibition in podocytes through autophagy inhibition via increasing PI3K/Akt signaling 31468575 96 Mouse CHCHD4P4 lncRNA glyoxylate kidney damage and kidney stones C57BL/6J mice glyoxylate upregulated 29160413 97 Mouse CHRF lncRNA isoprenaline cardiac hypertrophy primary cardiomyocytes isoprenaline (ISO) tteatment CHRF expression was upregulated and miR-93 expression was downregulated in mice and cellular models of cardiac hypertrophy. 29747050 98 Mouse CHRF lncRNA valsartan (VAL) doxorubicin (DOX)-induced cardiotoxicity primarymyocardialcells valsartan (VAL) treatment The expression of CHRF was downregulated by valsartan (VAL) treatment in doxorubicin (DOX)-induced heart failure 29124661 99 Mouse CHRF lncRNA doxorubicin (DOX) heart failure (HF) C57BL/6 male mice doxorubicin treatment upregulated 29124661 100 Mouse CHRF lncRNA IL-6 osteoarthritis (OA) ATDC5 cells IL-6 treatment IL©\6 upregulated lncRNA CHRF in ATDC5 cells. Overexpression of lncRNA CHRF aggravated IL©\6©\evoked inflammatory damages in ATDC5 cells. 31026064 101 Mouse COX2 lncRNA bacillus calmette-guerin (BCG) apoptosis RAW264.7 cells bacillus calmette-guerin (BCG) treatment upregulated 33250268 102 Mouse COX2 lncRNA bacillus calmette-guerin (BCG) apoptosis RAW264.7 cells bacillus calmette-guerin(BCG) infection "In this study, we found Bacillus Calmette-Guerin(BCG)infection induced cell apoptosis with a increasing LincRNA-Cox2 expression in RAW264.7 cells.?si-LincRNA-Cox2 was capable of increased the expression of apoptosis-associated proteins and accumulation of ROS in BCG-infected RAW264.7 cells." 33250268 103 Mouse COX2 lncRNA lipopolysaccharide (LPS) cell proliferation microglial cells lipopolysaccharide (LPS) treatment lincRNA-Cox2-siRNA loaded EVs also decreased LPS-induced microglial proliferation in mice. 31325121 104 Mouse COX2 lncRNA tumor necrosis factor alpha (TNF-¦Á) inflammatory response IEC cell line tumor necrosis factor alpha (TNF-¦Á) treatment "lincRNA-Cox2 silencing significantly (P < 005) enhanced the transcription of Il12b, a secondary late-responsive gene induced by TNF-¦Á Mechanistically, lincRNA-Cox2 promoted the recruitment of the Mi-2/nucleosome remodeling and deacetylase (Mi-2/NuRD) repressor complex to the Il12b promoter region" 26578685 105 Mouse COX2 lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment upregulated 32626785 106 Mouse COX2 lncRNA Rhein uric acid nephropathy (UAN) Mouse kidney epithelial cell line (TCMK-1) Rhein treatment Rhein attenuates inflammatory injury of TCMK-1 cells and represses lincRNA-Cox2 expression 32504995 107 Mouse COX2 lncRNA lipopolysaccharide (LPS) hepatocellular carcinoma (HCC) RAW264.7 macrophages lipopolysaccharide (LPS) treatment upregulated 29131381 108 Mouse COX2 lncRNA lipopolysaccharide (LPS) hepatocellular carcinoma (HCC) RAW264.7 macrophages lipopolysaccharide (LPS) treatment upregulated 29131381 109 Mouse COX2 lncRNA carbon tetrachloride (CCl4) liver fibrosis mouse carbon tetrachloride (CCl4) treatment upregulated 28259935 110 Mouse CRNDE lncRNA parathyroid hormone (PTH) bone metabolism MC3T3-E1 cells parathyroid hormone induction treatment Crnde regulates osteoblast proliferation through the Wnt/¦Â-catenin signaling pathway in mice 31622775 111 Mouse CRNDE lncRNA TGF-¦Â1 cardiac fibrosis cardiac fibroblasts (CFs) TGF-¦Â1 treatment upregulated 30748104 112 Mouse CRNDE lncRNA parathyroid hormone (PTH) cell differentiation MC3T3-E1 cells Parathyroid hormone (PTH) treatment upregulated 31622775 113 Mouse CRNDE lncRNA doxorubicin (DOX) heart failure (HF) HL-1 cells doxorubicin (Dox) treatment downregulated 33249529 114 Mouse CRNDE lncRNA dextran sodium sulfate (DSS) inflammatory bowel disease (IBD) colitis tissues dextran sulfate sodium (DSS) treatment CRNDE in the DSS-induced colitis tissues. 31251902 115 Mouse CRNDE lncRNA dexamethasone (DEX) osteoporosis human bone marrow mesenchymal stem cell (hBMSC) Dexamethasone (Dex) treatment "Dex downregulated CRNDE expression, whereas NBIF upregulated CRNDE." 33713471 116 Mouse CRNDE lncRNA neobavaisoflavone (NBIF) osteoporosis human bone marrow mesenchymal stem cell (hBMSC) Neobavaisoflavone (NBIF)? treatment "Dex downregulated CRNDE expression, whereas NBIF upregulated CRNDE." 33713471 117 Mouse CRNDE lncRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury mouse kidney tissues lipopolysaccharide (LPS) treatment upregulated 31841203 118 Mouse CTD-2574D22.4 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) mouse ATDC5 cells lipopolysaccharides (LPS) treatment upregulated 31368870 119 Mouse Cyrano lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment downregulated 32626785 120 Mouse CYTOR lncRNA angiotensin II (Ang II) cardiac hypertrophy primary cardiomyocyte angiotensin II (Ang II) treatment CYTOR knockdown significantly enhanced the inducible effect of AB operation on mice myocardial hypertrophy and Angiotensin II on cardiomyocyte hypertrophy. 30794866 121 Mouse D63785 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) neuron apoptosis SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 32999283 122 Mouse DACH1 lncRNA hypoxia heart failure (HF) heart tissues transverse aortic constriction surgery treatment upregulated 31446800 123 Mouse Dlk1-Dio3 lncRNA phenobarbital (PB) hepatocellular carcinoma (HCC) hepatocyte phenobarbital (PB) treatment Dlk1-Dio3 ncRNAs as novel candidate early biomarkers for mouse liver tumor promotion 23091169 124 Mouse Dlx6os1 lncRNA high glucose (HG) diabetic nephropathy (DN) SV40 MES13 cells high glucose (HG) treatment Long non-coding RNA Dlx6os1 serves as a potential treatment target for diabetic nephropathy via regulation of apoptosis and inflammation. 32855728 125 Mouse DNM3OS lncRNA high fat diet (HFD) diabetes mellitus (DM) peritoneal macrophages (PMs) high fat diet (HFD) feed upregulated 29930005 126 Mouse DNM3OS lncRNA high glucose (HG) diabetes mellitus (DM) bone marrow-derived macrophages (BMDMs) high glucose feed upregulated 29930005 127 Mouse DNM3OS lncRNA palmitic acid (PA) diabetes mellitus (DM) bone marrow-derived macrophages (BMDMs) palmitic acid (PA) treatment upregulated 29930005 128 Mouse DNM3OS lncRNA streptozocin (STZ) diabetes mellitus (DM) peritoneal macrophages (PMs) streptozotocin (STZ) treatment upregulated 29930005 129 Mouse DNM3OS lncRNA TGF-¦Â idiopathic pulmonary fibrosis (IPF) lung tissues transforming growth factor-¦Â (TGF-¦Â) treatment lncRNA DNM3OS was upregulated in TGF-¦Â treatment of lung fibroblastsinterfering with DNM3OS function not only prevents lung fibrosis but also improves established pulmonary fibrosis 30964696 130 Mouse DQ786227 lncRNA benzo(a)pyrene (BaP) lung cancer BEAS-2B cells benzo(a)pyrene (BaP) exposure lncRNA-DQ786227 acts as an oncogene in malignantly transformed BEAS-2B cells induced by benzo(a)pyrene 24084393 131 Mouse DSCAM-AS1 lncRNA angiotensin II (Ang II) cardiac hypertrophy cardiomyocytes angiotensin II (Ang II) treatment DSCAM-AS1 mediates pro-hypertrophy role of GRK2 in cardiac hypertrophy aggravation via absorbing miR-188-5p. 32377998 132 Mouse DYN-LRB2-2 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Raw264.7 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28815701 133 Mouse DYN-LRB2-2 lncRNA oxidized low density lipoprotein (ox-LDL) cholesterol efflux RAW 264.7 cells oxidized low-density lipoprotein (ox-LDL) treatment LincRNA DYN-LRB2-2 was upregulated in oxLDL-treated Raw264.7 cells. 28815701 134 Mouse E230001N04Rik lncRNA propofol (PPF) propofol-induced neurotoxicity hippocampus propofol treatment upregulated 29628875 135 Mouse E330013P06 lncRNA streptozocin (STZ) type 2 diabetes mellitus (T2DM) C57BL/6J mice macrophage "streptozotocin (50mg/kg) for 5 consecutive days. In diet-induced T2D models, f high-fat diet for 4 weeks and then inject a single dose of SZ (100mg/kg) treatment" upregulated 25008173 136 Mouse E52329 lncRNA Japanese encephalitis virus (JEV) neuroinflammation mouse brain infect with JEV dysregulated 29033949 137 Mouse Tmpo lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment downregulated 32246647 138 Mouse Gm15996 lncRNA high fat diet (HFD) male infertility C57bl/6J mice high fat diet (HFD) feed dysregulated 28599310 139 Mouse Mthfd2 lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment downregulated 32246647 140 Mouse BC012245.1 lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment upregulated 32246647 141 Mouse CCDS19728.1 lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment upregulated 32246647 142 Mouse ENSMUST00000053838 lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment upregulated 25827714 143 Mouse Gm7816 lncRNA X-rays radiation-induced injury mouse thymocytes X-ray irradiation upregulated 27864278 144 Mouse ENSMUST00000082683 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) placenta high fat diet (HFD) feed downregulated 29986645 145 Mouse Gm6166 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed downregulated 29986645 146 Mouse Gm11295 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed downregulated 29986645 147 Mouse Gm14328 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed downregulated 29986645 148 Mouse Hectd2os lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment ENSMUST00000129953 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 149 Mouse Hectd2os lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment downregulated 29115403 150 Mouse Hectd2os lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment ENSMUST00000129953 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 151 Mouse Gm13709 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment ENSMUST00000138573 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 152 Mouse Gm13709 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment downregulated 29115403 153 Mouse Gm13709 lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment ENSMUST00000138573 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 154 Mouse Dnm3os lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment upregulated 31833538 155 Mouse ENSMUST00000145208 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment ENSMUST00000145208 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 156 Mouse ENSMUST00000145208 lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment ENSMUST00000145208 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 157 Mouse F730043M19Rik lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment downregulated 31833538 158 Mouse BI665410.1 lncRNA streptozocin (STZ) diabetic neuropathic pain (DNP) mouse brain tissues streptozotocin treatment dysregulated 30599267 159 Mouse Ufm1-205 lncRNA cigarette smoke (CS) airway inflammation C57BL/6 mice lung tissue cigarette smoke (CS) exposure dysregulated 29383188 160 Mouse Hmcn1-205 lncRNA cigarette smoke (CS) airway inflammation C57BL/6 mice lung tissue cigarette smoke (CS) exposure dysregulated 29383188 161 Mouse Matr3-ps2-201 lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment upregulated 31833538 162 Mouse AK164970? lncRNA pressure overload heart failure (HF) heart sissues pressure overload treatment upregulated 33224746 163 Mouse AK079754.1 lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment downregulated 31833538 164 Mouse AA079447. lncRNA radiation radiation-induced intestinal injury intestinal tissues radiation treatment upregulated 30324649 165 Mouse Gm20662-201 lncRNA cigarette smoke (CS) airway inflammation C57BL/6 mice lung tissue cigarette smoke (CS) exposure dysregulated 29383188 166 Mouse Gm17501-201 lncRNA cigarette smoke (CS) airway inflammation C57BL/6 mice lung tissue cigarette smoke (CS) exposure dysregulated 29383188 167 Mouse Pigbos1-201 lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment upregulated 31833538 168 Mouse Gm10603-202 lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment upregulated 31833538 169 Mouse Gm38077-201 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) fetal mice palates "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" upregulated 31961203 170 Mouse BC016005.1 lncRNA Tripterysium Glycosides Tablets (TGT) rheumatoid arthritis (RA) peripheral blood Tripterysium Glycosides Tablets (TGT) treatment downregulated 33135351 171 Mouse DA040518.1 lncRNA carbon tetrachloride (CCl4) epithelial-mesenchymal transition (EMT) liver tissues carbon tetrachloride (CCl4) treatment "ENST00000530691, named Mical2, was significantly upregulated in liver fibrosis." 32659284 172 Mouse EPR lncRNA TGF-¦Â cell proliferation "Murine immortalized NMuMG cells, 4T1 mouse mammary gland cancer cells" TGF-¦Â treatment TGF-¦Â induced a small increase in EPR levels followed by rapid downregulated 31036808 173 Mouse EPS lncRNA caerulein (Cae) acute pancreatitis (AP) pancreases tissues caerulein (Cae) treatment "lincRNA-EPS was significantly downregulated in the pancreases from Cer-AP-10h mice, while it was dramatically upregulated in the pancreases from Cer-AP-22h mice." 33512718 174 Mouse EPS lncRNA sodium taurocholate acute pancreatitis (AP) pancreases tissues sodium taurocholate treatment "lincRNA-EPS was significantly downregulated in the pancreases from NaTc-SAP-2h mice, while it was dramatically upregulated in the pancreases from NaTc-SAP-24h and NaTc-SAP-36h mice" 33512718 175 Mouse Erbb4-IR lncRNA TGF-¦Â1 renal fibrosis "mTEC,MEF cells" TGF-¦Â1 treatment upregulated 29102563 176 Mouse Erbb4-IR lncRNA TGF-¦Â1 renal fibrosis mouse tubular epithelial cells (mTECs) TGF-¦Â1 treatment Erbb4-IR was upregulated by TGF-¦Â1 stimulation in a time- and dose-dependent manner 29102563 177 Mouse FAO lncRNA lipopolysaccharide (LPS) inflammation murine bone marrow-derived macrophages (BMDMs) lipopolysaccharide (LPS) treatment lncFAO is induced late after lipopolysaccharide (LPS) stimulation of cultured macrophages and in Ly6Chi monocyte-derived macrophages in damaged tissue during the resolution and reparative phases. 32513690 178 Mouse Fendrr lncRNA high glucose (HG) and hypoxia/reoxygenation (H/R) diabetic cerebral ischemia-reperfusion (I/R) injury BV-2 cells high glucose followed by hypoxia/reoxygenation (H/R) treatment "Fendrr was significantly increased in the diabetic cerebral I/R model, and NLRC4 inflammatory complex and pyroptosis mediated inflammatory factors were increased." 33858325 179 Mouse FENDRR lncRNA bleomycin (BLM) idiopathic pulmonary fibrosis (IPF) mouse lungs; primary lung fibroblasts bleomycin (BLM) treatment FENDRR reduced pulmonary fibrosis by inhibiting fibroblast activation by reducing iron concentration and acting as a competing endogenous RNA of the profibrotic microRNA-214. 31697569 180 Mouse FIRRE lncRNA lipopolysaccharide (LPS) neuropathic pain (NP) mouse microglial cells lipopolysaccharide (LPS) treatment FIRRE expression was upregulated in the spinal cord tissue of female CCI mice and LPS-induced microglial cells. 33151463 181 Mouse FIRRE lncRNA lipopolysaccharide (LPS) neuropathic pain (NP) mouse primary microglial cells lipopolysaccharide (LPS) treatment downregulated of lncRNA FIRRE relieved the neuropathic pain of female mice by suppressing HMGB1 expression. 33151463 182 Mouse FLRL2 lncRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) ¦Á-Mouse liver (AML) 12 cells free fatty acids treatment downregulated 31311301 183 Mouse FLRL2 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) Liver tissues high fat diet (HFD) feed downregulated 31311301 184 Mouse FOXC2-AS1 lncRNA doxorubicin (DOX) doxorubicin (DOX)-induced cardiotoxicity heart tissues doxorubicin (Dox) treatment FOXC2-AS1 was downregulated in heart tissues of mice with Dox-induced cardiotoxicity. 30558506 185 Mouse FOXC2-AS1 lncRNA doxorubicin (DOX) cardiotoxicity heart tissues doxorubicin (Dox)?treatment lncRNA FOXC2-AS1 may upregulate WISP1 to protect cardiomyocytes from doxorubicin-induced cardiotoxicity. 30558506 186 Mouse FOXD3-AS1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury N2a cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 33068927 187 Mouse FOXD3-AS1 lncRNA hyperoxia lung injury lung tissues treat with ROS upregulated 28655711 188 Mouse FR022494 lncRNA ovalbumin (OVA) allergic rhinitis (AR) CD4 + T cells ovalbumin (OVA) treatment upregulated 29287883 189 Mouse FR169472 lncRNA ovalbumin (OVA) allergic rhinitis (AR) CD4 + T cells ovalbumin (OVA) treatment upregulated 29287883 190 Mouse FR255904 lncRNA ovalbumin (OVA) allergic rhinitis (AR) CD4 + T cells ovalbumin (OVA) treatment upregulated 29287883 191 Mouse FR285768 lncRNA ovalbumin (OVA) allergic rhinitis (AR) CD4 + T cells ovalbumin (OVA) treatment downregulated 29287883 192 Mouse FR288904 lncRNA ovalbumin (OVA) allergic rhinitis (AR) CD4 + T cells ovalbumin (OVA) treatment downregulated 29287883 193 Mouse FR301516 lncRNA ovalbumin (OVA) allergic rhinitis (AR) CD4 + T cells ovalbumin (OVA) treatment downregulated 29287883 194 Mouse FTX lncRNA angiotensin II (Ang II) cardiac hypertrophy neonatal mouse cardiac myocytes angiotensin II (Ang II) treatment The expression of lnc-FTX was associated with reduced hypertrophy of neonatal mouse cardiac myocytes and regulated the PTEN/PI3K/Akt signaling pathway by sponging miRNA-22 31840653 195 Mouse FTX lncRNA H2O2 cardiomyocyte apoptosis cardiomyocytes were isolated from male mice treat with hydrogen peroxide downregulated 29117536 196 Mouse FTX lncRNA ischemia/reperfusion (I/R) cardiomyocyte apoptosis cardiomyocytes were isolated from male mice ischemia/reperfusion (I/R) treatment downregulated 29117536 197 Mouse FTX lncRNA H2O2 cardiovascular disease (CVD) cardiomyocytes hydrogen peroxide (H2O2 ) treatment lncRNA FTX is significantly downregulated upon ischemia/reperfusion injury and hydrogen peroxide treatment. 29117536 198 Mouse Galont lncRNA anoxia/reoxygenation (A/R) autophagy cardiomyocytes anoxia/reoxygenation (A/R) treatment Galont was upregulated by anoxia/reoxygenation (A/R) stimulus. 29247537 199 Mouse GAPLINC lncRNA lipopolysaccharide (LPS) endotoxic shock macrophages lipopolysaccharide (LPS) treatment "Upon inflammatory activation, GAPLINC is rapidly downregulated." 33568531 200 Mouse GAS5 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) Mouse hippocampal neuron HT22 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 33746585 201 Mouse GAS5 lncRNA qingda granule (QDG) ischemic stroke (IS) oxygen-glucose deprivation/reoxygenation (OGD/R) treated HT22 cells Qingda granule (QDG) treatment downregulated 33746585 202 Mouse GAS5 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) MLE-12 cells; lung tissues lipopolysaccharide (LPS) treatment GAS5 expression was decreased in lung tissues from LPS-induced ALI mice and LPS-treated MLE-12 cells. 31837322 203 Mouse GAS5 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) murine alveolar epithelial cell line MLE-12 lipopolysaccharide (LPS) treatment GAS5 suppresses inflammatory responses and apoptosis of alveolar epithelial cell MLE-12 by targeting miR-429/DUSP1 axis. 31837322 204 Mouse GAS5 lncRNA adjuvant adjuvant-induced arthritis (AIA) cartilage adjuvant treatment Long noncoding RNA-GAS5 siRNA prevented cartilage destruction by inhibiting miR-103 expression. 33343265 205 Mouse GAS5 lncRNA ovalbumin (OVA) allergic rhinitis (AR) CD4+ Th2 cells ovalbumin induction upregulated 32242002 206 Mouse GAS5 lncRNA arsenite arsenic-exposion male C57BL/6J mice arsenic (As) exposure downregulated 29132937 207 Mouse GAS5 lncRNA fasting with HIF-1¦Á inhibitor (BAY) cardiac decompensation secondary to acute severe caloric-restriction cardiac tissues Fasting with HIF-1¦Á inhibitor (BAY) treatment downregulated 32942153 208 Mouse GAS5 lncRNA triiodo-l-thyronine (T3) cardiac decompensation secondary to acute severe caloric-restriction cardiac tissues Triiodo-l-Thyronine (T3) treatment downregulated 32942153 209 Mouse GAS5 lncRNA isoproterenol cardiac fibrosis mouse heart tissues isoproterenol (ISO) treatment Overexpression of GAS5 could attenuate cardiac fibrosis induced by ISO. 31173316 210 Mouse GAS5 lncRNA lipopolysaccharide (LPS) cardiac fibrosis fibrotic heart tissues lipopolysaccharide (LPS) treatment downregulated 32008164 211 Mouse GAS5 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury Primary mouse cerebral cortical neurons oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31278927 212 Mouse GAS5 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury Mouse N2a neuroblastoma cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31751592 213 Mouse GAS5 lncRNA streptozocin (STZ) diabetes mellitus (DM) skin streptozotocin (STZ) treatment "GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model." 33865922 214 Mouse GAS5 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) newborn mouse cardiomyocyte (NMC) high glucose (HG) treatment Gas5/miR-320-3p/Tcf3 pathway was found to modulate the apoptosis of NMC. 32003049 215 Mouse GAS5 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) HL-1 cells high glucose (HG) treatment LncRNA GAS5 inhibits NLRP3 inflammasome activation-mediated pyroptosis in diabetic cardiomyopathy by targeting miR-34b-3p/AHR 33092444 216 Mouse GAS5 lncRNA danggui buxue tang (DBT) diabetic nephropathy (DN) high glucose-treated mouse mesangial cells (SV40 MES-13) danggui buxue tang (DBT) treatment upregulated 31481528 217 Mouse GAS5 lncRNA high glucose (HG) diabetic nephropathy (DN) mouse mesangial cells (SV40 MES-13) high glucose treatment downregulated 31481528 218 Mouse GAS5 lncRNA magnesium-free extracellular fluid epilepsy primary hippocampal neuron magnesium-free extracellular fluid culture "lncRNA GAS5 functions as a competitive endogenous RNA of miR-135a-5p to increase expression of KCNQ3, and lncRNA GAS5 silencing inhibited the occurrence and progression of epilepsy." 31373759 219 Mouse GAS5 lncRNA ¦Ã-rays gastrointestinal acute radiation syndrome Macrophages (M?) with the M2b phenotype (Pheno2b-M?) 7-10 Gy of gamma rays treatment downregulated 29743312 220 Mouse GAS5 lncRNA arsenite glucocorticoids (GCs) resistance utero arsenic (As) exposure Total cellular Gas5 levels were lower in arsenic-exposed males with no changes seen in arsenic-exposed females at GD16 and 18. 29132937 221 Mouse GAS5 lncRNA chlorogenic acid (CGA) intestinal diseases intestinal epithelial cells chlorogenic acid (CGA) treatment CGA promotes autophagy and inhibits ST infection through the GAS5/miR-23a/PTEN axis and the p38 MAPK pathway. 33240872 222 Mouse GAS5 lncRNA isosteviol Sodium (STV-Na) ischemic stroke (IS) microglia/macrophage polarization in ischemic stroke Isosteviol Sodium (STV-Na) treatment downregulated 31434993 223 Mouse GAS5 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) mouse primary brain neurons oxygen-glucose deprivation (OGD) treatment GAS5 level was elevated in neurons subjected to OGD compared with the control group 29307821 224 Mouse GAS5 lncRNA hypoxia cardiomyocytes injury HL-1 Cells hypoxia exposure miR-222-3p could resume the functions of GAS5 in cell viabilities and apoptosis through protein regulation in PI3K and AKT signaling pathways. 32240616 225 Mouse GAS5 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) ATDC5 cells lipopolysaccharide (LPS) treatment "LPS reduced cell viability and promoted cell apoptosis and secretion of inflammatory cytokines, along with downregulated of GAS5." 29448248 226 Mouse GAS5 lncRNA rotenone (ROT) parkinson's disease (PD) brain tissues rotenone treatment upregulated 32470877 227 Mouse GAS5 lncRNA ZCL-082 premature ovarian failure (POF) female germline stem cell (FGSC) ZCL-082 treatment downregulated 31319247 228 Mouse GAS5 lncRNA high fat diet (HFD) and streptozotocin (STZ) renal fibrosis kidney tissues high fat diet (HFD) and streptozotocin (STZ) treatment LncRNA Gas5(GAS5) expression was increased in kidneys of the DKD mouse model. 31810140 229 Mouse GAS5 lncRNA lipopolysaccharide (LPS) sepsis podocyte lipopolysaccharide (LPS) treatment GAS5 expression decreased in a time-dependent manner in LPS-induced podocytes. 30556845 230 Mouse GAS5 lncRNA dexamethasone (DEX) severe asthma (SA) lung tissues dexamethasone (DEX) treatment downregulated 32642099 231 Mouse GAS5 lncRNA ovalbumin (OVA) and lipopolysaccharide (LPS) severe asthma (SA) lung tissues ovalbumin (OVA) and lipopolysaccharide (LPS) treatment upregulated 32642099 232 Mouse GAS5 lncRNA TGF-¦Â tissue fibrosis NIH-3T3 cells Transforming growth factor-¦Â (TGF-¦Â) treatment LncRNA GAS5 attenuates fibroblast activation through inhibiting Smad3 signaling 32374674 233 Mouse GAS5 lncRNA H2O2 traumatic brain injury (TBI) retinal ganglion cells (RGCs) H2O2 treatment upregulated 30450834 234 Mouse GAS5 lncRNA traditional Chinese medicine Changqin NO. 1 traumatic brain injury (TBI) brain tissues and primary neurons traditional Chinese medicine Changqin NO. 1 treatment Changqin NO 1 promoted neuroprotective effects by inhibiting neuronal apoptosis via the GAS5/miR-335/Rasa1 axis in TBI 30653462 235 Mouse Gm11149 lncRNA carbon tetrachloride (CCl4) liver fibrosis liver tissues carbon tetrachloride (CCl4) treatment upregulated 30193772 236 Mouse Gm11529 lncRNA dexamethasone (DEX) asthma lung tissues dexamethasone (Dex) treatment Gm11529 was downregulated in the Dex group compared with that in the Model group. 32222886 237 Mouse Gm11974 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury N2a cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment Gm11974 was mainly located in cytoplasm Knockdown of lncRNA Gm11974 alleviated the apoptosis induced by OGD and cell death rates were significantly reduced 31556305 238 Mouse Gm11985 lncRNA propofol (PPF) acute neurotoxicity hippocampus propofol treatment downregulated 30261491 239 Mouse Gm12840 lncRNA TGF-¦Â1 ischemia/reperfusion (I/R) injury kidney tissues TGF-¦Â1 treatment LncRNA (Gm12840) could act as a sponge for miR-677-5p to mediate fibroblast activation induced by TGF-¦Â1 via the WISP1/PKB (Akt) signaling pathway 33351669 240 Mouse Gm13133 lncRNA cold obesity mouse brown adipose cold treatment upregulated 28247947 241 Mouse Gm13133 lncRNA "¦Â3 -adrenergic agonist ,cAMP" obesity mouse brown adipose ¦Â3 -adrenergic agonist and cAMP treatment upregulated 28247947 242 Mouse Gm13372 lncRNA dexamethasone (DEX) asthma lung tissues dexamethasone (Dex) treatment Gm13372 was upregulated in the Dex group compared with that in the Model group. 32222886 243 Mouse Gm13910 lncRNA chronic intermittent hypoxia (CIH) atherosclerosis (AS) aorta tissues Chronic intermittent hypoxia (CIH) treatment upregulated 32328084 244 Mouse Gm14205 lncRNA hormone postpartum depression (PPD) hippocampus hormone treatment Gm14205 induces astrocytic NLRP3 inflammasome activation via inhibiting oxytocin receptor in postpartum depression. 32706026 245 Mouse Gm14461 lncRNA lipopolysaccharide (LPS) trigeminal neuralgia (TN) astrocytes lipopolysaccharide (LPS) treatment Silencing of lncRNA Gm14461 alleviates pain in trigeminal neuralgia through inhibiting astrocyte activation. 33141516 246 Mouse Gm15621 lncRNA sevoflurane (SEV) cognitive impairment primary hippocampal neuron cells sevoflurane exposure treatment The expression of lncRNA Gm15621 was decreased with the development of sevoflurane exposure 31264218 247 Mouse Gm15621 lncRNA sevoflurane (SEV) cognitive impairment Primary hippocampal neuron cells "To establish an in vitro sevoflurane©\ induced neurotoxicity model, the primary hippocampal neuron cells were treated with different concentrations of sevoflurane for 6 hr treatment" lncRNA Gm15621 located in the cytoplasm The expression of lncRNA Gm15621 was decreased with the development of sevoflurane exposure Overexpression of lncRNA Gm15621 significantly reduced the apoptosis and cell survival rates 31264218 248 Mouse Gm15622 lncRNA metformin (Met) nonalcoholic fatty liver disease (NAFLD) AML-12 cells metformin treatment Metformin suppresses Gm15622 and alleviates NAFLD-associated lipid deposition in mice. 32229588 249 Mouse Gm15645 lncRNA high glucose (HG) diabetic nephropathy (DN) primary mouse podocyte cells high glucose (HG) treatment Gm15645 was significantly downregulated in podocytes under high glucose conditions. 30132544 250 Mouse Gm15834 lncRNA angiotensin II (Ang II) cardiac hypertrophy The cardiomyocyte-like HL-1 cell lines angiotensin II (Ang II) treatment upregulated 33130312 251 Mouse Gm15834 lncRNA angiotensin II (Ang II) cardiac hypertrophy HL-1 cells angiotensin II (Ang II) treatment upregulated 33130312 252 Mouse Gm15851 lncRNA prenatal nicotine exposure (PNE) POMC neuronal development and/or function POMC neurons prenatal nicotine exposure (PNE) treatment upregulated 27609221 253 Mouse Gm16343 lncRNA IL-36¦Â colorectal cancer (CRC) CD8+ T cells interleukin 36¦Â treatment upregulated 31684829 254 Mouse Gm16410 lncRNA particulate matter (PM2.5) PM2.5-induced lung inflammation RAW264.7 cells fine particulate matter (PM2.5) treatment "The result showed that a significant reduction in expression of one lncRNA, identified as lncGm16410, was observed in the lung of mice and RAW2647 cells following exposure to PM25" 33796524 255 Mouse Gm16410 lncRNA particulate matter (PM2.5) lung fibrosis mouse pulmonary vascular endothelial cells (MHCs) PM2.5 exposure treatment The involvement of lncRNA Gm16410 in PM25-induced EndMT highlights the potential of lncRNA to promote pulmonary fibrosis under environmental pollution 32961493 256 Mouse Gm17501 lncRNA dexamethasone (DEX) asthma lung tissues dexamethasone (Dex) treatment Gm13372 was upregulated in the Dex group compared with that in the Model group. 32222886 257 Mouse Gm20319 lncRNA subchronic deoxynivalenol (DON) liver damage liver tissues; Hepa 1-6 cells subchronic deoxynivalenol (DON) exposure treatment upregulated 32439590 258 Mouse Gm20471 lncRNA carbon tetrachloride (CCl4) liver fibrosis liver tissues carbon tetrachloride (CCl4) treatment upregulated 30193772 259 Mouse Gm2199 lncRNA carbon tetrachloride (CCl4) liver damage liver tissues; AML12 cells carbon tetrachloride (CCl4) treatment Gm2199 was downregulated in both damaged livers and hepatocyte lines. 29789577 260 Mouse Gm26917 lncRNA high glucose (HG) diabetic nephropathy (DN) mesangial cell ?high glucose (HG)?treatment treatment The expression of Gm26917 was induced by HG but weakened by RSG 33790061 261 Mouse Gm26917 lncRNA rosiglitazone diabetic nephropathy (DN) mesangial cell Rosiglitazone (RSG) treatment The expression of Gm26917 was induced by HG but weakened by RSG 33790061 262 Mouse Gm34934 lncRNA "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)" rheumatoid arthritis (RA) TM3 Leydig cells "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment" upregulated 33360214 263 Mouse Gm43050 lncRNA sevoflurane (SEV) sevoflurane-induced abnormal cognition primary hippocampal neurons sevoflurane treatment Overexpression of lncRNA Gm43050 alleviates apoptosis and inflammation response induced by sevoflurane treatment by regulating miR-640/ZFP91 32913509 264 Mouse Gm43181 lncRNA ventilator ventilator-induced lung injury (VILI) mouse lung tissues ventilator treatment lncRNA Gm43181 might be related to lung damage and neutrophil activation via chemokine receptor chemokine (C-X-C) receptor 2 30784114 265 Mouse Gm43652 lncRNA adipogenesis medium muscle cells during adipogenic transdifferentiation C2C12 cells "adipogenesis medium (DMEM-F12, 20% fetal calf serum, 10 ?g/mL insulin, 1 ?M dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 10 ?M rosiglitazone) treatment" upregulated 31366088 266 Mouse Gm5091 lncRNA alcohol alcoholic liver fibrosis (ALF) mouse primary hepatic stellate cells alcohol treatment LncRNA Gm5091 was sharply downregulated in HSCs of mouse AHF in vivo and alcohol-treated primary HSCs in vitro. 29935035 267 Mouse Gm5421 lncRNA chronic intermittent hypoxia (CIH) atherosclerosis (AS) aorta tissues Chronic intermittent hypoxia (CIH) treatment upregulated 32328084 268 Mouse Gm5524 lncRNA high glucose (HG) diabetic nephropathy (DN) primary mouse podocyte cells high glucose (HG) treatment Gm5524 was additionally significantly upregulated in podocytes under high glucose conditions. 30132544 269 Mouse Gm9926 lncRNA 5-aminolevulinic acid photodynamic therapy(ALA-PDT) colitis colon tissues 5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment downregulated 30385297 270 Mouse Gomafu lncRNA berberine (BBR) obesity-induced chronic inflammation RAW264.7 ; 3T3-L1 preadipocytes berberine (BBR) treatment Overexpression of lncRNA Gomafu partially blocked the protective effects of berberine in free fatty acids-treated adipocytes by increasing endoplasmic reticulum stress. 32650294 271 Mouse Gpr137b-ps lncRNA carbon tetrachloride (CCl4) liver fibrosis hepatic stellate cells (HSCs) carbon tetrachloride (CCl4) treatment ?lncRNA G protein-coupled receptor 137B (Gpr137b-ps) and C-X-C motif chemokine ligand 14 (CXCL14) showed to be markedly upregulated within carbon tetrachloride (CCl4)-caused hepatic fibrotic mice tissue samples and activated HSCs. 33069761 272 Mouse Gpr137b-ps lncRNA carbon tetrachloride (CCl4) liver fibrosis carbon tetrachloride (CCl4) treatment lncRNA Gpr137b-ps/miR-200a-3p/CXCL14 axis that modulates HSC activation and might exert an effect on the pathogenesis of liver fibrosis. 33069761 273 Mouse H19 lncRNA hypoxia acute myocardial infarction (AMI) mouse HL-1 cells hypoxia upregulated 29179202 274 Mouse H19 lncRNA benzyl butyl phthalate (BBP) adipogenesis Multipotent C3H10T1/2 cells benzyl butyl phthalate (BBP) treatment Cells treated with an 8 day BBP regimen showed that H19 expression was decreased at day 2 with 50 ¦ÌM BBP exposure 33395283 275 Mouse H19 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) brain tissues amyloid-¦Â (A¦Â) 25-35 treatment "Elevated H19, HMGB1 and decreased miR-129 were found in A¦Â25-35-treated PC12 cells as well as in brain tissues of AD mice." 33410377 276 Mouse H19 lncRNA dexamethasone (DEX) asthma lung tissues dexamethasone (Dex) treatment H19 was upregulated in the Dex group compared with that in the Model group. 32222886 277 Mouse H19 lncRNA astragaloside IV (AS-IV) atherosclerosis (AS) vascular smooth muscle cells from high-fat diet fed ApoE-/- mice astragaloside (AS-IV) treatment upregulated 30529164 278 Mouse H19 lncRNA high fat diet (HFD) atherosclerosis (AS) ApoE-/- mice vascular smooth muscle cells high fat diet (HFD) feed downregulated 30529164 279 Mouse H19 lncRNA high fat diet (HFD) atherosclerosis (AS) aortic tissues of atherosclerosis mice high fat diet (HFD) feed upregulated 31757932 280 Mouse H19 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) RAW264.7 cells oxidized low-density lipoprotein (ox-LDL) treatment Increased expression of H19 was detected in ox-LDL-treated Raw264.7 cells. 29172088 281 Mouse H19 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Raw264.7 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29172088 282 Mouse H19 lncRNA hyperoxia bronchopulmonary dysplasia (BPD) lung tissues hyperoxia (Hyp) treatment Downregulated lncRNA H19 relieved pulmonary injury via targeting miR-17 to downregulate STAT3 and reduced inflammatory response caused by p-STAT3 in BPD newborn mice. 33285606 283 Mouse H19 lncRNA high glucose (HG) cardiomyocyte senescence Neonatal mouse ventricular cells (NMVCs) high glucose (HG) treatment H19 level was significantly increased in high glucose-induced senescence cardiomyocytes and aged mouse hearts. 33664669 284 Mouse H19 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) mouse palatal tissues "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" upregulated 29081343 285 Mouse H19 lncRNA all-trans retinoic acid (ATRA) cleft palate (CP) fetuses all-trans retinoic acid (ATRA) treatment "In addition, the the relationship between lncRNA H19 and IGF2 were negative correlation in the critical period of developmental palate" 27307343 286 Mouse H19 lncRNA all-trans retinoic acid (ATRA) cleft palate (CP) C57BL/6 mice all-trans retinoic acid (ATRA) treatment upregulated 27307343 287 Mouse H19 lncRNA azoxymethane (AOM) and dextran sulfate sodium (DSS) AOM/DSS colitis-associated colon cancer (CAC) colon tissues azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment H19 was highly expressed in the tumor tissues of CAC mice compared with the expression in normal colon tissues. 30083271 288 Mouse H19 lncRNA streptozocin (STZ) diabetes mellitus (DM) hippocampal neurons streptozotocin (STZ) treatment "Higher lncRNA H19 expression was found in DM Upregulated lncRNA H19 significantly increased the expression of Bax and caspase-3 but decreased that of Bcl-2, thus promoting the apoptosis of hippocampal neuron" 30536889 289 Mouse H19 lncRNA metformin (Met) diabetic nephropathy (DN) SV40-MES-13 cells Metformin (MET) treatment "Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-¦Â1 axis." 32391614 290 Mouse H19 lncRNA synthetic preimplantation factor (sPIF) duchenne muscular dystrophy (DMD) myoblast Synthetic preimplantation factor (sPIF) treatment upregulated 30692507 291 Mouse H19 lncRNA TGF-¦Â hepatocellular carcinoma (HCC) tumor-initiating hepatocytes (TICs) TGF-¦Â treatment TGF-¦Â treatment reduced H19 expression 30014520 292 Mouse H19 lncRNA bleomycin (BLM) idiopathic pulmonary fibrosis (IPF) lung fibrosis tissues bleomycin (BLM) treatment The level of H19 was upregulated in the lung fibrosis tissue compared with the control group treated with saline. 29411215 293 Mouse H19 lncRNA bleomycin (BLM) idiopathic pulmonary fibrosis (IPF) lung tissues bleomycin (BLM) treatment upregulated 33138822 294 Mouse H19 lncRNA TGF-¦Â1 inflammation MAC-T cells TGF-¦Â1 treatment upregulated 29062612 295 Mouse H19 lncRNA hypoxia ischemic stroke (IS) mouse plasma ;white blood cells;brain tissues middle cerebral artery occlusion (MCAO) treatment "upregulated in plasma, white blood cells, and brain" 28630232 296 Mouse H19 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) HT22 cells oxygen-glucose deprivation (OGD) treatment Long non-coding RNA H19 inhibition ameliorates oxygen-glucose deprivation-induced cell apoptosis and inflammatory cytokine expression by regulating the microRNA-29b/SIRT1/PGC-1¦Á axis 33313940 297 Mouse H19 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) mouse HT22 cells oxygen-glucose deprivation (OGD) treatment "In the present study, MCAO model mice and OGD-treated cells displayed significantly increased lncRNA H19 expression levels compared with sham mice and control cells, respectively" 33313940 298 Mouse H19 lncRNA glyoxylate kidney tubular cell injury renal tubular epithelial cell glyoxylate treatment upregulated 31735555 299 Mouse H19 lncRNA glyoxylate kidney tubular cell injury oxidative stress glyoxylate treatment upregulated 31735555 300 Mouse H19 lncRNA carbon tetrachloride (CCl4) liver fibrosis liver tissues carbon tetrachloride (CCl4) treatment upregulated 30362572 301 Mouse H19 lncRNA carbon tetrachloride (CCl4) liver fibrosis mouse liver tissue carbon tetrachloride (CCl4) treatment upregulated 30362572 302 Mouse H19 lncRNA H2O2 liver fibrosis AML12 cells H2O2 treatment upregulated 32579217 303 Mouse H19 lncRNA TGF-¦Â liver fibrosis "mouse Primary hepatic stellate cells (PHSCs), The human immortalized HSC line LX©\2,Human L©\02 hepatocytes" TGF-¦Â treatment upregulated 30362572 304 Mouse H19 lncRNA "diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC)" liver preneoplastic foci and tumors mice liver cells "Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC) treatment" upregulated 19362547 305 Mouse H19 lncRNA high fat diet (HFD) male infertility C57bl/6J mice high fat diet (HFD) feed dysregulated 28599310 306 Mouse H19 lncRNA metformin (Met) metabolic disorders mouse fetuses Metformin treatment upregulated 29215608 307 Mouse H19 lncRNA CoCl2 myocardial infarction (MI)-induced heart failure (HF) Cardiac progenitor cells (CPCs) CoCl2 treatment The expression of long non-coding RNA H19 was significantly downregulated in CPCs after hypoxia stimuli. 30137188 308 Mouse H19 lncRNA 6-Gingerol (6-G) myocardial ischemia/reperfusion (I/R) injury (MIRI) HL-1 cells 6-Gingerol (6-G) treatment we found that 6-G elevated cellular H19 expression in hypoxia/reoxygenation (H/R)-treated HL-1 cells. 33758383 309 Mouse H19 lncRNA H2O2 myocardial ischemia/reperfusion (I/R) injury (MIRI) cardiomyocytes H2O2 treatment downregulated 31284127 310 Mouse H19 lncRNA berberine (BBR) nonalcoholic fatty liver disease (NAFLD) mouse liver berberine (BBR) treatment BBR's beneficial effects are linked with the downregulated of microRNA34a and long noncoding RNA H19 33494295 311 Mouse H19 lncRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) primary cultured hepatocytes free fatty acids treatment upregulated 29140550 312 Mouse H19 lncRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) cultured mouse primary hepatocytes free fatty acid (FFA) treatment upregulated 31064820 313 Mouse H19 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) liver tissues high fat diet (HFD) feed upregulated 29140550 314 Mouse H19 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) liver tissues high fat diet (HFD) feed upregulated 31064820 315 Mouse H19 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) liver tissues high fat diet (HFD) feed H19 was upregulated during the development of high-fat diet (HFD)-induced NAFLD. 31809000 316 Mouse H19 lncRNA oleic acid (OA) nonalcoholic fatty liver disease (NAFLD) primary mouse hepatocytes oleic acid (OA) treatment H19 was upregulated in oleic acid-induced steatosis. 31809000 317 Mouse H19 lncRNA bone morphogenetic protein 9 (BMP9) osteogenesis mouse mesenchymal stem cell (MSC) lines iMEFs and iMADs bone morphogenetic protein 9 (BMP9) treatment upregulated 28881833 318 Mouse H19 lncRNA metformin (Met) oxidative stress N2a cells metformin treatment metformin inhibited the expression of lncRNA-H19 in both MCAO/R-treated mice and OGD/R-treated N2a cells. 31934270 319 Mouse H19 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" H19 was downregulated in brain tissues of MPTP-induced PD mice (in vivo). 32356199 320 Mouse H19 lncRNA 6-hydroxydopamine (6-OHDA) parkinson's disease (PD) dopaminergic neuron 6-hydroxydopamine (6-OHDA) treatment LncRNA H19 diminishes dopaminergic neuron loss by mediating microRNA-301b-3p in Parkinson's disease via the HPRT1-mediated Wnt/¦Â-catenin signaling pathway. 32434961 321 Mouse H19 lncRNA monocrotaline (MCT) pulmonary arterial hypertension (PAH) serum; lungs tissues monocrotaline (MCT) treatment H19 was highly expressed in the serum and lungs of MCT-induced models. 30547791 322 Mouse H19 lncRNA arsenite lung fibrosis murine bone marrow-derived macrophages (BMDMs) arsenic (As) exposure downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages. 33162208 323 Mouse H19 lncRNA arsenite lung fibrosis lung tissues; bone marrow-derived macrophages (BMDMs) arsenite exposure upregulated 33162208 324 Mouse H19 lncRNA dextran sodium sulfate (DSS) regeneration of the intestinal epithelia intestinal tissues dextran sulfate sodium (DSS) treatment upregulated 29621481 325 Mouse H19 lncRNA lipopolysaccharide (LPS) regeneration of the intestinal epithelia intestinal tissues lipopolysaccharide (LPS) treatment upregulated 29621481 326 Mouse H19 lncRNA lipopolysaccharide (LPS) sepsis mice cardiomyocytes UL-1 cells lipopolysaccharide (LPS) treatment downregulated 30021355 327 Mouse H19 lncRNA lipopolysaccharide (LPS) spinal cord injury (SCI) BV2 cells lipopolysaccharides (LPS) treatment LncRNA H19 Regulates Lipopolysaccharide (LPS)-Induced Apoptosis and Inflammation of BV2 Microglia Cells Through Targeting miR-325-3p/NEUROD4 Axis. 33205379 328 Mouse H19 lncRNA high fat diet (HFD) type 2 diabetes mellitus (T2DM) liver tissues high fat diet (HFD) feed Hepatic H19 expression is chronically increased in diabetic mice. 29769440 329 Mouse H19 lncRNA cinnamaldehyde (CA) ulcerative colitis (UC) colonic tissues Cinnamaldehyde (CA) treatment lncRNA H19 was increased in the colonic tissues of the DSS-treated mice compared with the normal mice at 7 days or 14 days and was significantly decreased on day 14 after CA administration. 33341041 330 Mouse H19 lncRNA cigarette smoke extract (CSE) smoke-induced lung injury (SILI) lung tissues cigarette smoke extract (CSE) treatment upregulated 33523607 331 Mouse H19 lncRNA Rb3 smoke-induced lung injury (SILI) lung tissues Rb3 treatment downregulated 33523607 332 Mouse HAGLROS lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) mouse midbrain tissues 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 31298038 333 Mouse HCG18 lncRNA high glucose (HG) diabetic peripheral neuropathy (DPN) macrophage high glucose (HG) treatment LncRNA HCG18 was highly expressed in DPN model and HG-induced macrophages. 32996080 334 Mouse HCP5 lncRNA oxygen glucose deprivation (OGD) cerebral ischemia/reperfusion (I/R) injury N2a cells oxygen glucose deprivation (OGD) treatment upregulation of lncRNA HCP5 may exacerbate cerebral ischemic reperfusion injury by sponging miR-652-3p 32657103 335 Mouse HIF1A-AS1 lncRNA coxsackievirus B3 (CVB3) acute viral myocarditis (VM) mouse myocardium; primary cardiomyocytes Coxsackievirus B3 (CVB3) infection lncRNA HIF1A-AS1 promotes NF-¦ÊB signaling and subsequently aggravates cardiomyocyte apoptosis and inflammation via targeting miR-138. 33224748 336 Mouse HIF1A-AS2 lncRNA flagellin intestinal inflammation ulcerative colitis samples flagellin treatment Flagellin induced HIF1A-AS2 expression in a dose- and time-dependent manner via p38-stat1 activation. 29772233 337 Mouse HOTAIR lncRNA coronary artery ligation acute myocardial infarction (AMI) C57BL/6J mice serum subjected to coronary artery ligation downregulated 29258067 338 Mouse HOTAIR lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Raw264.7 cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30402866 339 Mouse HOTAIR lncRNA angiotensin II (Ang II) cardiac fibrosis primary cultured cardiac fibroblasts (CFs) angiotensin II (Ang II) treatment upregulated 30402865 340 Mouse HOTAIR lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) H9c2 cells high glucose (HG) treatment HOTAIR was downregulated in HG-stimulated H9c2. 30216438 341 Mouse HOTAIR lncRNA streptozocin (STZ) diabetic cardiomyopathy (DCM) mouse heart tissues streptozotocin (STZ) treatment HOTAIR protected against DCM via activation of the SIRT1 expression by sponging miR-34a 30216438 342 Mouse HOTAIR lncRNA high glucose (HG) diabetic nephropathy (DN) conditionally immortalised mouse podocytes high glucose (HG) treatment upregulated 31399844 343 Mouse HOTAIR lncRNA streptozocin (STZ) diabetic nephropathy (DN) kidney tissues streptozotocin treatment upregulated 31399844 344 Mouse HOTAIR lncRNA high glucose (HG) diabetic retinopathy (DR) Retinal endothelial cell (REC) dysfunction high glucose treatment upregulated 32812634 345 Mouse HOTAIR lncRNA carbon tetrachloride (CCl4) liver fibrosis liver tissues carbon tetrachloride (CCl4) treatment upregulated 30673982 346 Mouse HOTAIR lncRNA rosiglitazone liver fibrosis TGF-¦Â1 treated primary mouse hepatic stellate cells (HSCs) Rosiglitazone (RGZ) treatment downregulated 30673982 347 Mouse HOTAIR lncRNA rosiglitazone liver fibrosis carbon tetrachloride (CCl4) treated mouse liver tissues Rosiglitazone (RGZ) treatment downregulated 30673982 348 Mouse HOTAIR lncRNA TGF-¦Â1 liver fibrosis Primary mouse hepatic stellate cells (HSCs) TGF-¦Â1 treatment upregulated 30673982 349 Mouse HOTAIR lncRNA high fat diet (HFD) hepatic insulin resistance liver tissues high fat diet (HFD) feed "HOTAIR was significantly upregulated in T2D patients, C57BL/6J mice fed with a high-fat diet." 30536334 350 Mouse HOTAIR lncRNA H2O2 hepatic ischemia/reperfusion injury (HIRI) Primary mouse hepatocytes culture H2O2 treatment knockdown of the expression of HOTAIR attenuated autophagy induced by hydrogen peroxide. 30367982 351 Mouse HOTAIR lncRNA lipopolysaccharide (LPS) inflammation RAW264.7 macrophages lipopolysaccharide (LPS) treatment HOTAIR expression is induced in immune cells (macrophages) upon treatment with lipopolysaccharide (LPS). 30353135 352 Mouse HOTAIR lncRNA lipopolysaccharide (LPS) inflammation RAW264.7 cells lipopolysaccharide (LPS) treatment upregulated 33420270 353 Mouse HOTAIR lncRNA ischemia myocardial ischemia/reperfusion (I/R) injury (MIRI) Plasma left anterior descending artery (LAD) ligation HOTAIR aggravates myocardial IR by competitively binding SRSF1 with microRNA-126. 32964995 354 Mouse HOTAIR lncRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment upregulated 32315726 355 Mouse HOTAIR lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) mouse brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 28445933 356 Mouse HOTAIR lncRNA arsenite lung fibrosis lung tissues arsenite exposure upregulated 33162208 357 Mouse HOTAIR lncRNA cecal ligation and puncture (CLP) sepsis Monocytes were isolated from the spleens cecal ligation and puncture induce upregulated 31656541 358 Mouse HOTAIR lncRNA silicon dioxide (SiO2) silicosis HBE and A549 cells silicon dioxide (SiO2) treatment "miR-326 is downregulated in the fibrotic lung tissues of silica-treated mice, while increased expression of miR-326 attenuates silica-induced pulmonary fibrosis in vivo" 31642316 359 Mouse HOTAIR lncRNA lipopolysaccharide (LPS) traumatic brain injury (TBI) BV2 cells; primary microglia lipopolysaccharide (LPS) treatment upregulated 32602030 360 Mouse HOTAIR lncRNA lipopolysaccharide (LPS) traumatic brain injury (TBI) primary mouse microglia lipopolysaccharide (LPS) treatment LncRNA HOTAIR was abnormally highly expressed in activated microglia. 32602030 361 Mouse HOTTIP lncRNA high glucose (HG) diabetic nephropathy (DN) SV40-MES13 cells high-glucose (HG) treatment upregulated 31934070 362 Mouse HOTTIP lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) primary cortical neurons oxygen-glucose deprivation (OGD) treatment downregulated 30129112 363 Mouse HOTTIP lncRNA carbon tetrachloride (CCl4) liver fibrosis hepatic stellate cells (HSCs) CCl4 treatment upregulated 30548190 364 Mouse HOTTIP lncRNA carbon tetrachloride (CCl4) liver fibrosis liver tissues carbon tetrachloride (CCl4) treatment HOTTIP expressions in fibrotic liver samples and cirrhotic liver samples were significantly upregulated compared with healthy liver controls. 30562760 365 Mouse HOX lncRNA carbon tetrachloride (CCl4) liver fibrosis mouse CCl4 treatment upregulated 27979710 366 Mouse HOXA11-AS lncRNA TGF-¦Â1 cardiac fibrosis mouse cardiac fibroblasts (CFs) TGF¦Â1 treatment upregulated 30720066 367 Mouse HOXA11-AS1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) substantia nigra (SN) area "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" "?HOXA11-AS promoted MPTP-mediated SH-SY5Y neuronal injury and LPS-induced microglia activation, while miR-124-3p had the opposite effects." 33839699 368 Mouse HOXA11-AS1 lncRNA lipopolysaccharide (LPS) parkinson's disease (PD) BV2 cells lipopolysaccharide (LPS) treatment upregulated 33839699 369 Mouse Hoxaas3 lncRNA bleomycin (BLM) idiopathic pulmonary fibrosis (IPF) lung fibroblasts bleomycin (BLM) treatment upregulated 32848140 370 Mouse Hoxaas3 lncRNA hypoxia pulmonary hypertension (PH) lung vasculature of hypoxic mice and in pulmonary artery smooth muscle cells (PASMCs) under hypoxic conditions hypoxia induce upregulated 30304383 371 Mouse Hsp4 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) MLE-12 cells lipopolysaccharide (LPS) treatment Hsp4 alleviates lipopolysaccharide-induced apoptosis of lung epithelial cells via miRNA-466m-3p/DNAjb6 axis. 32976821 372 Mouse HULC lncRNA tumor necrosis factor alpha (TNF-¦Á) osteoarthritis (OA) ?ATDC5 cells tumor necrosis factor alpha (TNF-¦Á) treatment ?HULC protected ATDC5 cells against TNF-¦Á-induced inflammatory injury by repression of miR-101 30981080 373 Mouse IGF2 lncRNA ketamine neurotoxicity neural stem cell culture ketamine treatment upregulated 27914827 374 Mouse IGF2AS lncRNA ketamine neurotoxicity E18.5 brain-derived neural stem cells ketamine treatment upregulated 27914827 375 Mouse IUR lncRNA imatinib leukemia Abl-transformed primary bone marrow cells imatinib treatment Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. 30961617 376 Mouse Jak3 lncRNA monosodium urate (MSU) cell differentiation RAW264.7 cells Monosodium urate monohydrate (MSU) treatment upregulated 30387921 377 Mouse KCNQ1OT1 lncRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) serums acetaminophen (APAP) treatment downregulated 32779042 378 Mouse KCNQ1OT1 lncRNA angiotensin II (Ang II) atrial fibrillation (AF) heart tissues angiotensin II (Ang II) treatment LncRNA KCNQ1 overlapping transcript 1 (KCNQ1OT1) was found to be significantly upregulated in AF model and Ang-II-induced mice heart. 30241939 379 Mouse KCNQ1OT1 lncRNA arsenic trioxide (ATO) cardiac arrhythmia primary cultured neonatal mouse cardiomyocytes arsenic trioxide (ATO) treatment "After ATO treatment, the Kcnq1ot1 and Kcnq1 expression levels were downregulated." 29675399 380 Mouse KCNQ1OT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury primary mouse cerebral cortical neurons oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 32912499 381 Mouse KCNQ1OT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury mouse primary cortical neurons oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31837324 382 Mouse KCNQ1OT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury primary cortical neurons oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31837324 383 Mouse KCNQ1OT1 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) primary cardiomyocytes high glucose (HG) treatment upregulated 30355944 384 Mouse KCNQ1OT1 lncRNA streptozocin (STZ) diabetic cardiomyopathy (DCM) heart tissues streptozotocin (STZ) treatment upregulated 30355944 385 Mouse KCNQ1OT1 lncRNA doxorubicin (DOX) heart failure (HF) HL-1 cells doxorubicin (ADR) treatment KCNQ1OT1 facilitates cardiomyocyte apoptosis by - targeting FUS in ADR-induced HF. 32497620 386 Mouse KCNQ1OT1 lncRNA platelet derived growth factor-BB (PDGF-BB) intimal hyperplasia (IH) vascular smooth muscle cells (VSMCs) platelet-derived growth factor type BB (PDGF-BB) treatment downregulated 32146419 387 Mouse KCNQ1OT1 lncRNA hypoxia myocardial ischemia/reperfusion (I/R) injury (MIRI) primary cultured cardiomyocyte hypoxia induce upregulated 31644943 388 Mouse KCNQ1OT1 lncRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) cardiomyocytes hypoxia/reoxygenation (H/R) treatment "KCNQ1OT1 could promote the LGALS3 expression by binding to miR-204-5p, which led to aggravated myocardial IR injury." 31644943 389 Mouse KCNQ1OT1 lncRNA resveratrol osteoblastic differentiation mouse mesenchymal stem cells (mMSCs) resveratrol (Res) treatment upregulated 29541443 390 Mouse KCNQ1OT1 lncRNA polymethylmethacrylate (PMMA) particle-induced osteolysis (PIO) primary bone marrow-derived macrophages (BMMs) polymethylmethacrylate (PMMA) treatment KCNQ1OT1 was suppressed in PMMA-induced cells 29252185 391 Mouse KCNQ1OT1 lncRNA sublytic complement C5b-9 (sC5b-9) renal inflammatory diseases MPC5 cells sublytic complement C5b-9 (sC5b-9) treatment upregulated 33296289 392 Mouse KCNQ1OT1 lncRNA sublytic complement C5b-9 (sC5b-9) renal inflammatory diseases MPC5 cells sublytic complement C5b-9 (sC5b-9) treatment Kcnq1ot1 was upregulated in sC5b-9-induced podocytes 33296289 393 Mouse LET lncRNA hypoxia hepatocellular carcinoma (HCC) and colorectal cancer (CRC) SMMC-7721 cells; HCCLM3 cells; SW480 cells Hypoxia treatment downregulated 23395002 394 Mouse Lethe lncRNA sepsis sepsis-induced brain injury (SIBI) cerebral cortex tissues cecal ligation and puncture (CLP) induce treatment upregulated 31210319 395 Mouse LGR lncRNA fasting expression regulation plasma fasting treatment upregulated 26904944 396 Mouse Lin28B lncRNA angiotensin II (Ang II) allergic airway inflammation murine bone marrow-derived macrophages (BMDMs) angiotensin II (Ang II) treatment upregulated 32458348 397 Mouse LINC00261 lncRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury kidney tissues lipopolysaccharide (LPS) treatment "In this study, we found the expression of LINC00261 was significantly decreased in the serum of patients with sepsis than healthy controls. A similar result was also observed in the mouse model of sepsis induced by lipopolysaccharide (LPS)." 33481135 398 Mouse LINC00261 lncRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury pulmonary microvascular endothelial cells (PMVECs) lipopolysaccharide (LPS) treatment downregulated 33481135 399 Mouse LINC00305 lncRNA lipopolysaccharide (LPS) inflammation ATDC5 cells lipopolysaccharide (LPS) treatment upregulated 31190561 400 Mouse LINC00511 lncRNA H2O2 ischemia/reperfusion (I/R) injury Primary cardiomyocytes H2O2 treatment LINC00511 accelerates the proliferation of cardiomyocytes after I/R by targeting miRNA-515-5p. 32141575 401 Mouse LINC00968 lncRNA high glucose (HG) diabetic nephropathy (DN) mouse mesangial cells high glucose (HG) treatment lncRNA LINC00968 expression was high-expressed in high-glucose induced mesangial cells. 30197001 402 Mouse LINC01093 lncRNA carbon tetrachloride (CCl4) apoptosis liver tissues CCl4 treatment upregulated 32044992 403 Mouse LINC01093 lncRNA TGF-¦Â1 apoptosis NCTC 146 TGF-¦Â1 treatment upregulated 32044992 404 Mouse LINC01152 lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) "Huh7, HepG2 and Hep3B cells" hepatitis B virus (HBV) infection upregulated 31054511 405 Mouse Lincs_chr17_4383_2 lncRNA trichloroethylene (TCE) trichloroethylene (TCE) hepatocarcinogenesis liver tissues Trichloroethylene (TCE) treatment "TCE induced extensive LincRNA expression changes in mouse liver, and the downregulated of Liver Lincs_chr17_4383_2 might contribute to TCE hepatocarcinogenesis by interacting with miR-182-5p and Cdkn1a" 31942800 406 Mouse LINK-A lncRNA high glucose (HG) diabetic nephropathy (DN) mouse podocyte cells high glucose treatment downregulated 31258644 407 Mouse LNC_000898 lncRNA hypoxia myocardial infarction (MI) neonatal mouse ventricular cardiomyocytes (NMCMs) hypoxia treatment LNC_000898 could protect the heart against MI injury by regulating miR-375/PDK1. 32398474 408 Mouse LNC_000941 lncRNA ischemia/reperfusion (I/R) acute kidney injury (AKI) kidney tissues ischemia/reperfusion (I/R) treatment dysregulated 29245971 409 Mouse lnc010561 lncRNA melatonin breast cancer mouse breast cancer cell lines 4T1 and MA-891 Melatonin treatment downregulated 31955008 410 Mouse lnc010561 lncRNA melatonin breast cancer ?4T1 cells; 891 cells Melatonin treatment Melatonin regulated breast cancer progression by the lnc010561/miR-30/FKBP3 axis. 31955008 411 Mouse lnc949 lncRNA bleomycin and engeletin lung fibrosis myofibroblasts bleomycin and engeletin treatment Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-¦Â1-Smad2/3 and JNK signalling pathways 33181025 412 Mouse linc-p21 lncRNA immunoglobulin E (IgE) abdominal aortic aneurysm (AAA) aortic tissues asthma-induced high level of IgE upregulated 31440377 413 Mouse linc-p21 lncRNA streptozocin (STZ) diabetes mellitus (DM) hippocampal neuron streptozotocin induce treatment "lincRNA p21 were poorly expressed lincRNA p21 overexpression in the diabetes mice reduced the cell apoptosis rate, and the expression of Bax and cleaved Caspase-3, whereas increase the Bcl-2 expression" 31081202 414 Mouse lncRNA30245 lncRNA TGF-¦Â1 myocardial infarction (MI) cardiac fibroblasts (CFs) transforming growth factor (TGF)-¦Â1 treatment upregulated 30935639 415 Mouse lncRNA430945 lncRNA angiotensin II (Ang II) atherosclerosis (AS) mouse vascular smooth muscle cells (VSMCs) angiotensin II (Ang II) treatment The downregulated of lncRNA 430945 significantly suppressed AngII-induced VSMC proliferation and migration. 30957191 416 Mouse lncRNA6406 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) renal tubular epithelial (PTEC) cells; kidney tissues lipopolysaccharide (LPS) treatment LncRNA 6406 is downregulated both in the Kidneys of mice in the LPS-induced AKI Model and LPS-stimulated in vitro Model. 32655407 417 Mouse lncRNA9884 lncRNA protocatechualdehyde (PCA) tubulointerstitial fibrosis (TIF) primary renal tubular epithelial cells (TECs) protocatechualdehyde (PCA) treatment Protocatechualdehyde attenuates obstructive nephropathy through inhibiting lncRNA9884 induced inflammation 33118280 418 Mouse LOC102633466 lncRNA aerobic exercise parkinson's disease (PD) striatal tissues aerobic exercise training (AET) treatment upregulated 33150124 419 Mouse LOC102637865 lncRNA aerobic exercise parkinson's disease (PD) striatal tissues aerobic exercise training (AET) treatment upregulated 33150124 420 Mouse LOC102637887 lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment downregulated 32246647 421 Mouse LOC102638670 lncRNA aerobic exercise parkinson's disease (PD) striatal tissues aerobic exercise training (AET) treatment upregulated 33150124 422 Mouse LOC102638971 lncRNA oxygen retinopathy of prematurity (ROP) retinal tissues oxygen treatment upregulated 32246647 423 Mouse LOC102640519 lncRNA hypoxia cerebral ischemia injury (CII) mice brain microvascular endothelial cells oxygen-glucose deprivation reperfusion (OGD/R) treatment downregulated 29842876 424 Mouse LOC102640519 lncRNA vascular endothelial growth factor (VEGF) cerebral ischemia injury (CII) oxygen-glucose deprivation reperfusion (OGD/R) treated mice brain microvascular endothelial cells oxygen-glucose deprivation reperfusion (OGD/R) treatment upregulated 29842876 425 Mouse LOC105375913 lncRNA complement C3a focal segmental glomerulosclerosis (FSGS) tubular cells C3a treatment upregulated 30679767 426 Mouse LOC146880 lncRNA particulate matter (PM2.5) lung cancer lung tissue PM2.5 treatment upregulated 27836757 427 Mouse LOC498759 lncRNA glucocorticoid-inducible kinase-1 (SGK1) diabetic nephropathy (DN) mouse podocytes glucocorticoid-inducible kinase-1 (SGK1) treatment upregulated 31564202 428 Mouse LOC498759 lncRNA high glucose (HG) diabetic nephropathy (DN) mouse podocytes high glucose (HG) treatment upregulated 31564202 429 Mouse LOC498759 lncRNA Jixuepaidu Tang-1 diabetic nephropathy (DN) high glucose (HG) treated mouse podoccytes Jixuepaidu Tang-1 treatment downregulated 31564202 430 Mouse LOC498759 lncRNA TGF-¦Â1 diabetic nephropathy (DN) mouse podocytes Transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 31564202 431 Mouse LRCF lncRNA propofol (PPF) cognitive function "Primary neonatal mouse oligodendrocyte (OLGs), microglia (MGs) and neuron cells (NCs)" propofol treatment ?Our systematic study showed that LRCF expression differs in OLGs of mice of different ages 33411226 432 Mouse LRNA9884 lncRNA cisplatin (DDP) acute kidney injury (AKI) murine renal proximal tubular epithelial cells (mTECs) cisplatin treatment upregulated 33192605 433 Mouse LRNA9884 lncRNA advanced glycation end product (AGE) diabetic nephropathy (DN) immortalized murine kidney proximal tubular epithelial (mTEC) cells advanced glycation end products (AGE) treatment upregulated 31048367 434 Mouse Lrrc55-AS lncRNA herpes simplex virus 1 (HSV-1) innate immune response mouse peritoneal macrophages Herpes Simplex Virus( HSV) infection upregulated 31213650 435 Mouse Lrrc55-AS lncRNA IFN-I innate immune response mouse peritoneal macrophages IFN-I treatment upregulated 31213650 436 Mouse Lrrc55-AS lncRNA lipopolysaccharide (LPS) innate immune response mouse peritoneal macrophages lipopolysaccharides (LPS) treatment upregulated 31213650 437 Mouse Lrrc55-AS lncRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune response mouse peritoneal macrophages poly (I: C)) treatment upregulated 31213650 438 Mouse Lrrc55-AS lncRNA Sendai virus (SeV) innate immune response mouse peritoneal macrophages Sendai virus (SeV) infection treatment upregulated 31213650 439 Mouse MAGI2-AS3 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) BV2 cells amyloid-¦Â (A¦Â) 25-35 treatment "The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35." 33279663 440 Mouse MAGI2-AS3 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) BV2 cells amyloid-¦Â (A¦Â) 25-35 treatment MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells. 33279663 441 Mouse MALAT lncRNA hypoxia renal proximal tubular function kidney tissues;testis tissues hypoxia treatment upregulated 27774481 442 Mouse MALAT1 lncRNA hypoxia acute myocardial infarction (AMI) Cardiomyocytes hypoxia induce upregulated 31783925 443 Mouse MALAT1 lncRNA hypoxia/reoxygenation (H/R) acute myocardial infarction (AMI) The mouse cardiomyocyte cell line HL-1 hypoxia/reperfusion induce upregulated 32010261 444 Mouse MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) angiogenesis mouse brain microvascular endothelial cells (BMECs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment the levels of lncRNA-MALAT1 and miR-145 were upregulated in OGD-induced BMECs miR-145 functioned as an anti-angiogenic and pro-apoptotic factor in OGD treated BMECs via down-regulating VEGF-A and ANGPT2 directly 30038058 445 Mouse MALAT1 lncRNA insulin brain injury human adipose-derived stem cells (hASCs) insulin treatment upregulated 27841943 446 Mouse MALAT1 lncRNA fasting with HIF-1¦Á inhibitor (BAY) cardiac decompensation secondary to acute severe caloric-restriction cardiac tissues Fasting with HIF-1¦Á inhibitor (BAY) treatment downregulated 32942153 447 Mouse MALAT1 lncRNA triiodo-l-thyronine (T3) cardiac decompensation secondary to acute severe caloric-restriction cardiac tissues Triiodo-l-Thyronine (T3) treatment downregulated 32942153 448 Mouse MALAT1 lncRNA angiotensin II (Ang II) cardiac fibrosis cardiac fibroblasts angiotensin II (Ang II) treatment upregulated 30146700 449 Mouse MALAT1 lncRNA melatonin cardiac fibrosis high glucose (HG)-treated cardiac fibroblasts (CFs) Melatonin treatment melatonin produces an antifibrotic effect via inhibiting lncR-MALAT1/miR-141-mediated NLRP3 inflammasome activation and TGF-¦Â1/Smads signaling 32067273 450 Mouse MALAT1 lncRNA hypoxia/reoxygenation (H/R) cardiomyocyte apoptosis cardiomyocytes hypoxia/reoxygenation (H/R) treatment Long noncoding RNA MALAT1 enhances the apoptosis of cardiomyocytes through autophagy modulation. 31985274 451 Mouse MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral palsy N2A neurons oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 31500509 452 Mouse MALAT1 lncRNA high glucose (HG) and hypoxia/reoxygenation (H/R) diabetes mellitus (DM) induced cerebral ischemic reperfusion (I/R) injury rat primary microglia; HAPI cells high glucose (HG) and hypoxia-reoxygenation (H/R) treatment upregulated 29844328 453 Mouse MALAT1 lncRNA streptozocin (STZ) diabetes-related microvascular complications db/db mice retinal vasculature STZ treatment upregulated 25356875 454 Mouse MALAT1 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) cardiomyocytes high glucose (HG) treatment upregulated 31353329 455 Mouse MALAT1 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) primary cultured cardiomyocyte high glucose treatment upregulated 31353329 456 Mouse MALAT1 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) mouse cardiomyocytes high glucose (HG) treatment MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy. 33097254 457 Mouse MALAT1 lncRNA streptozocin (STZ) diabetic cardiomyopathy (DCM) myocardium streptozocin treatment upregulated 31353329 458 Mouse MALAT1 lncRNA streptozocin (STZ) diabetic cardiomyopathy (DCM) myocardial tissues streptozotocin (STZ) treatment upregulated 31353329 459 Mouse MALAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) MPC5 cells high glucose (HG) treatment LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy 33232688 460 Mouse MALAT1 lncRNA streptozocin (STZ) diabetic nephropathy (DN) C57BL/6 mice kidney streptozocin (STZ) treatment upregulated 28444861 461 Mouse MALAT1 lncRNA high glucose (HG) diabetic retinopathy (DR) retinal endothelial cells high glucose (HG) treatment Glucose increased LncRNA?MALAT1?levels by increasing Sp1 transcription factor binding at its promoter. 33051272 462 Mouse MALAT1 lncRNA high glucose (HG) diabetic retinopathy (DR) retinal microvascular endothelial cells (RMECs) high glucose treatment upregulated 31313295 463 Mouse MALAT1 lncRNA oxygen diabetic retinopathy (DR) mouse retinal tissues oxygen induce treatment upregulated 31689123 464 Mouse MALAT1 lncRNA oxygen diabetic retinopathy (DR) retinal tissues oxygen treatment MALAT1 affect angiogenesis by sponging miR-203a-3p in DR 31689123 465 Mouse MALAT1 lncRNA streptozocin (STZ) diabetic retinopathy (DR) RF/6A cell streptozotocin treatment upregulated 24436191 466 Mouse MALAT1 lncRNA streptozotocin injection and a high-glucose/high-fat diet diabetic retinopathy (DR) retinal microvascular endothelial cells (RMECs) streptozotocin injection and a high-glucose/high-fat diet treatment "YAP1 may exert some promotive effects on the development of DR through its regulation of the MALAT1/miR-200b-3p/VEGFA axis, highlighting that YAP1 silencing may be instrumental for the therapeutic targeting of DR" 31313295 467 Mouse MALAT1 lncRNA high fat diet (HFD) epithelial-mesenchymal transition (EMT) ApoE-/- mice arterial tissue high fat diet (HFD) feed upregulated 30871555 468 Mouse MALAT1 lncRNA CoCl2 heart failure (HF) cardiac progenitor cells (CPCs) CoCl2 treatment long non-coding RNA MALAT1 expression was significantly upregulated in the CoCl 2-induced hypoxia CPC model. 29605300 469 Mouse MALAT1 lncRNA CoCl2 heart failure (HF) cardiac stem cells (CSCs) CoCl2 treatment upregulated 30362213 470 Mouse MALAT1 lncRNA hypoxia hypoxic/ischemic brain damage (HIBD) mouse primary hippocampal neurons hypoxia induce upregulated 31185248 471 Mouse MALAT1 lncRNA exercise (Ex) insulin resistance (IR) serum from IR mouse swimming downregulated 31479923 472 Mouse MALAT1 lncRNA high-fat high-fructose diet (HFHFD) insulin resistance (IR) subcutaneous white adipose tissue (scWAT) high-fat-high-sucrose diet feed downregulated 29746487 473 Mouse MALAT1 lncRNA fentanyl ischemia/reperfusion (I/R) injury "HL-1, a cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte" fentanyl treatment downregulated 27862640 474 Mouse MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemia/reperfusion (I/R) injury astrocyte cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment MALAT1 promotes cerebral ischemia-reperfusion injury by affecting AQP4 expression through competitively binding miR-145 32138732 475 Mouse MALAT1 lncRNA hypoxia ischemic brain injury Neuronal Cells middle cerebral artery occlusion (MCAO) treatment upregulated 28854438 476 Mouse MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic brain injury Mouse brain MEC line bEnd.3 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 29203245 477 Mouse MALAT1 lncRNA CoCl2 ischemic heart disease (IHD) cardiac stem cells (CSCs) CoCl 2 treatment CoCl2 induced a dose-dependent increase in MALAT1 mRNA levels. 30362213 478 Mouse MALAT1 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) bEnd.3 cells Oxygen-glucose deprivation (OGD) treatment Long noncoding RNA MALAT1 regulates apoptosis in ischemic stroke by sponging miR-205-3p and modulating PTEN expression 32655805 479 Mouse MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) brain microvascular endothelial cell (BMEC) of C57BL/6J mice oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 28433650 480 Mouse MALAT1 lncRNA palmitate cell proliferation hepatocytes palmitate treatment upregulated 26935028 481 Mouse MALAT1 lncRNA arsenite liver fibrosis mouse liver tissues arsenite exposure "In mice, MALAT1 was overexpressed in the progression of liver fibrosis induced by arsenite" 31513886 482 Mouse MALAT1 lncRNA myostatin hepatic insulin resistance mouse Hepa-1c1c7 myostatin treatment downregulated 24882465 483 Mouse MALAT1 lncRNA IL-4 macrophage polarization Mouse bone marrow-derived macrophages (BMDMs) IL-4 treatment downregulated 30676324 484 Mouse MALAT1 lncRNA lipopolysaccharide (LPS) macrophage polarization Mouse bone marrow-derived macrophages (BMDMs) lipopolysaccharide (LPS) treatment upregulated 30676324 485 Mouse MALAT1 lncRNA hypoxia/reoxygenation (H/R) myocardial infarction (MI) HL-1 cardiomyocytes hypoxia/reoxygenation (H/R) induce upregulated 31227612 486 Mouse MALAT1 lncRNA hypoxia/reoxygenation (H/R) myocardial infarction (MI) HL-1 cells hypoxia/reoxygenation (H/R) treatment LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5 32010261 487 Mouse MALAT1 lncRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) HL-1 cells hypoxia-reoxygenation (H/R)treatment downregulated 27862640 488 Mouse MALAT1 lncRNA nitrogen dioxide (NO2) neurodevelopmental disorder cortex nitrogen dioxide (NO2) treatment upregulated 32203807 489 Mouse MALAT1 lncRNA bupivacaine neurotoxicity Primary dorsal root ganglion (DRG) neurons bupivacaine treatment "The expression of lncRNA MALAT1 was upregulated upon exposure to bupivacaine. Knockdown of lncRNA MALAT1 significantly increased the cell death rates, and Caspase3 activity assays revealed that the apoptosis rates were manifestly increased in the MALAT1 downregulated group." 31254586 490 Mouse MALAT1 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) ATDC5 cells lipopolysaccharide (LPS) treatment MALAT1 was upregulated in LPS-stimulated ATDC5 cells. 30145831 491 Mouse MALAT1 lncRNA streptozocin (STZ) oxidative stress retinal microvessels streptozocin (STZ) treatment upregulated 33051272 492 Mouse MALAT1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) midbrain samples "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 30260025 493 Mouse MALAT1 lncRNA resveratrol parkinson's disease (PD) Parkinson's disease (PD) mice midbrain samples resveratrol (RS) treatment downregulated 30260025 494 Mouse MALAT1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" "The expression levels of MALAT1 and leucine-rich repeat kinase (LRRK2) were increased, and that of miR-205-5p was decreased in the midbrains of mice in which PD was induced by MPTP." 29511451 495 Mouse MALAT1 lncRNA ¦Â-Asarone parkinson's disease (PD) midbrain ¦Â-Asarone treatment downregulated 27470562 496 Mouse MALAT1 lncRNA oxygen pathological neovascularization mouse ocular neovascularization exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment dysregulated 24623407 497 Mouse MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) post-stroke angiogenesis A mouse brain microvascular endothelial cell line oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 30784209 498 Mouse MALAT1 lncRNA oxygen glucose deprivation (OGD) post-stroke brain damage mouse brain microvascular endothelial cells (BMECs) oxygen and glucose deprivation treatment upregulated 28093478 499 Mouse MALAT1 lncRNA berberine (BBR) post-stroke inflammation ipsilateral cortex tissues berberine (BBR) treatment Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation. 31431734 500 Mouse MALAT1 lncRNA berberine (BBR) post-stroke inflammation MCAO treated ipsilateral cortex tissues ?berberine (BBR)?treatment treatment downregulated 31431734 501 Mouse MALAT1 lncRNA arsenite lung fibrosis lung tissues arsenite exposure upregulated 33162208 502 Mouse MALAT1 lncRNA silica lung fibrosis mouse lung tissues silica treatment upregulated in 28900284 503 Mouse MALAT1 lncRNA hypoxia renal ischemia/reperfusion (I/R) injury HK-2 cells and HUVEC cells hypoxia induce upregulated 29467431 504 Mouse MALAT1 lncRNA oxygen retinopathy of prematurity (ROP) retinas oxygen treatment upregulated 32827542 505 Mouse MALAT1 lncRNA lipopolysaccharide (LPS) sepsis HL-1 cells lipopolysaccharide (LPS) treatment upregulated 28165557 506 Mouse MALAT1 lncRNA lipopolysaccharide (LPS) sepsis mouse macrophage cell line RAW264.7 lipopolysaccharide (LPS) treatment "MALAT1 inhibited RAW264.7?cell proliferation, while miR-346 promoted its proliferation." 31494280 507 Mouse MALAT1 lncRNA lipopolysaccharide (LPS) sepsis skeletal muscle tissues lipopolysaccharide (LPS) treatment upregulated 31830649 508 Mouse MALAT1 lncRNA lipopolysaccharide (LPS) sepsis Skeletal Muscle Tissues lipopolysaccharide (LPS) treatment upregulated 32882524 509 Mouse MALAT1 lncRNA lipopolysaccharide (LPS) sepsis-induced acute lung injury lung tissues lipopolysaccharide (LPS) treatment upregulated 30779099 510 Mouse MALAT1 lncRNA hypoxia stroke mouse brain microvascular endothelial cells (BMECs) oxygen-glucose deprivation (OGD) induce the levels of lncRNA-MALAT1 and miR-145 were upregulated in OGD-induced BMECs. miR-145 functioned as an anti-angiogenic and pro-apoptotic factor in OGD treated BMECs via down-regulating VEGF-A and ANGPT2 directly. 30038058 511 Mouse MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) testicular ischemia-reperfusion injury (IRI) GC-1 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment lncRNA MALAT1 was involved in the response to testicular IRI and cellular OGD/R 29870987 512 Mouse MALAT1 lncRNA streptozocin (STZ) tubular injury kidney tissues streptozotocin (STZ) treatment LncRNA MALAT1 was upregulated in kidney tissues of diabetic mice 29928873 513 Mouse MALAT1 lncRNA palmitate ¦Â-cell dysfunction MIN6 cells palmitate treament treatment exendin-4 ameliorated ¦Â-cell impairment by Pdx1-mediated Malat1 upregulation 32324218 514 Mouse MALAT1 lncRNA cigarette smoke extract (CSE) ¦Â-cell dysfunction MIN6 cells cigarette smoke extract (CSE) treatment cigarette smoke extract (CSE) increased the levels of MALAT1. 29856480 515 Mouse MEG3 lncRNA all-trans retinoic acid (ATRA) cleft palate (CP) mouse embryonic palate mesenchymal (MEPM) cells all-trans retinoic acid (ATRA) treatment upregulated 33493612 516 Mouse MEG3 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) kidney tissues lipopolysaccharide (LPS) treatment MEG3 was significantly increased in kidney tissues induced by lipopolysaccharide (LPS). 29923218 517 Mouse MEG3 lncRNA chronic intermittent hypoxia (CIH) aortic endothelial function aortic endothelial cells chronic intermittent hypoxia (CIH) treatment MEG3 suppresses the apoptosis of aortic endothelial cells in mice with chronic intermittent hypoxia via downregulated of HIF-1¦Á by competitively binding to microRNA-135a. 32642094 518 Mouse MEG3 lncRNA high fat diet (HFD) atherosclerosis (AS) endothelium high fat diet (HFD) feed Melatonin significantly diminished MEG3 expression. 29024030 519 Mouse MEG3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) mouse Raw264.7 cells oxidized low-density lipoprotein (ox-LDL) treatment ox-LDL upregulated MEG3 expression and that knockdown of MEG3 inhibited the action of ox-LDL in Raw264.7 cells. 30672051 520 Mouse MEG3 lncRNA angiotensin II (Ang II) cardiac hypertrophy Cardiomyocytes isolated from newborn mouse hearts angiotensin II (Ang II) treatment MEG3 was upregulated in the cardiomyocytes which were treated with Ang-II. 30679521 521 Mouse MEG3 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury BV-2 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment MEG3 could alleviate cerebral I/R injury via inhibiting M1 polarization and promoting M2 polarization through Kr¨¹ppel-like factor 4 (KLF4) 33180644 522 Mouse MEG3 lncRNA hypoxia cerebral ischemic stroke (CIS) C57BL/6 J mice MCAO treatment upregulated 29238035 523 Mouse MEG3 lncRNA high glucose (HG) diabetes mellitus (DM) primary hepatocytes high glucagon treatment MEG3 was highly expressed in high glucagon-treated mouse primary hepatocytes. 30260029 524 Mouse MEG3 lncRNA high glucose (HG) diabetic nephropathy (DN) MPC5 cells high glucose (HG) treatment downregulated 31799068 525 Mouse MEG3 lncRNA streptozocin (STZ) diabetic retinopathy (DR) retinal endothelial cell STZ treatment downregulated 26845358 526 Mouse MEG3 lncRNA atorvastatin heart failure (HF) cardiac progenitor cell (CPC) atorvastatin treatment downregulated 30481260 527 Mouse MEG3 lncRNA high glucagon hepatic gluconeogenesis mouse primary hepatocytes high glucagon treatment MEG3 was highly expressed in high glucagon-treated mouse primary hepatocytes. 30260029 528 Mouse MEG3 lncRNA high fat diet (HFD) hepatic insulin resistance primary hepatocytes high fat diet (HFD) feed upregulated 26603935 529 Mouse MEG3 lncRNA high fat diet (HFD) hepatic insulin resistance mouse liver tissues high fat diet (HFD) feed upregulated 30431065 530 Mouse MEG3 lncRNA palmitate hepatic insulin resistance mouse primary hepatocytes palmitate treatment upregulated 30431065 531 Mouse MEG3 lncRNA ischemia hepatic ischemia/reperfusion injury (HIRI) HL7702 cells hepatic ischemia-reperfusion (HIR) upregulated 28708282 532 Mouse MEG3 lncRNA hyperoxia hyperoxia-induced acute lung injury (HALI) MLE-12 cells hyperoxia treatment upregulated 32084370 533 Mouse MEG3 lncRNA hypoxia hypoxic pulmonary hypertension (HPH) pulmonary artery smooth muscle cells (PASMCs) hypoxia induce lncRNA-MEG3 was significantly increased and primarily localized in the cytoplasm of hypoxic PASMCs. Silencing of lncRNA-MEG3 by siRNAs and gapmers attenuated proliferation and cell-cycle progression in both PASMCs from idiopathic pulmonary arterial hypertension (iPAH) patients (iPAH-PASMCs) and hypoxia-exposed PASMCs in vitro. 31477557 534 Mouse MEG3 lncRNA oxygen glucose deprivation (OGD) intracerebral haemorrhage (ICH) Primary brain microvascular endothelial cells (BMECs) oxygen-and-glucose-deprivation (OGD) treatment upregulated 33836898 535 Mouse MEG3 lncRNA carbon tetrachloride (CCl4) liver fibrosis male C57BL/6J mice CCl4 treatment downregulated 25201080 536 Mouse MEG3 lncRNA "diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC)" liver preneoplastic foci and tumors mice liver cells "Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC) treatment" downregulated 19362547 537 Mouse MEG3 lncRNA morphine morphine addiction HT22 cells Morphine treatment upregulated 31433241 538 Mouse MEG3 lncRNA IL-1¦Â osteoarthritis (OA) "CHON-001, ATDC5 cells" IL-1¦Â treatment "MEG3 expression in chondrocytes was downregulated by the stimulation of IL-1¦Â, and MEG3 negatively regulated miR-9-5p expression but positively regulated KLF4 expression." 33776787 539 Mouse MEG3 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) ATDC5 cells lipopolysaccharide (LPS) treatment "LPS decreased cell viability, increased cell apoptosis, promoted the release of pro-inflammatory factors, and downregulated MEG3 expression." 29432995 540 Mouse MEG3 lncRNA streptozocin (STZ) podocyte injury mouse podocytes streptozotocin (STZ) treatment upregulated 33061608 541 Mouse MEG3 lncRNA cyclophosphamide (CP) pathological senescence mouse ovarian granulosa cells cyclophosphamide (CP) treatment upregulated 27729272 542 Mouse MEG3 lncRNA melatonin protecting neural stem cells (NSCs) from reactive oxygen species (ROS) neural stem cells Melatonin treatment melatonin appeared to protect NSCs from H2O2-induced ROS by modification of the MEG3/miRNA-27a-3p/MAP2K4 axis. 32599124 543 Mouse MEG3 lncRNA mycobacterium tuberculosis (Mtb) pulmonary tuberculosis (PTB) RAW264.7 cells mycobacterium tuberculosis (MTB) infection MEG3 was highly expressed in PTB. 33035634 544 Mouse MEG3 lncRNA light retinal degenerative diseases retina light exposure Light exposure leads to increased MEG3 expression. 29409883 545 Mouse MEG3 lncRNA ultraviolet (UV) irradiation skin damage primary murine skin fibroblasts UVB treatment "The overexpression of Meg3 after UVB irradiation was observed in primary murine skin fibroblasts, and the upregulated Meg3 expression was related to the activation of the inflammatory cytokines" 31761787 546 Mouse MEG3 lncRNA lipopolysaccharide + ATP traumatic brain injury (TBI) microglia lipopolysaccharide + ATP treatment upregulated 33189612 547 Mouse MEG3 lncRNA high fat diet (HFD) type 2 diabetes mellitus (T2DM) primary hepatocytes high fat diet (HFD) feed upregulated 26603935 548 Mouse MEG3 lncRNA coxsackievirus B3 (CVB3) viral myocarditis (VM) macrophages coxsackievirus B3 (CVB3) treatment "downregulated of MEG3 leads to the inhibition of inflammation and induces M2 macrophage polarization via miR-223/TRAF6/NF-¦ÊB axis, thus alleviating VMC." 33047847 549 Mouse MEG3-4 lncRNA P. aeruginosa strain PAO1 bacterial infection lung tissues P. aeruginosa strain PAO1 treatment MEG3-4 is in a decreased abundance in mouse lungs after bacterial infection 29945883 550 Mouse MEG8 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) Mouse brain microvascular endothelial cells (BMECs) oxygen glucose deprivation (OGD) treatment upregulated 32627090 551 Mouse MEG9 lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment upregulated 32626785 552 Mouse Mhrt lncRNA hearts pressure-overloaded pathological hypertrophy mouse transaortic constriction (TAC)3 treatment downregulated 25119045 553 Mouse Mhrt779 lncRNA exercise (Ex) physiological myocardial hypertrophy (PMH) heart tissues exercise treatment Mhrt779?was one of the markedly upregulated long noncoding RNAs in the EHP group. 33757294 554 Mouse MIAT lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) primary cardiomyocytes; fibroblasts high glucose (HG) treatment upregulated 32351959 555 Mouse MIAT lncRNA streptozocin (STZ) diabetic retinopathy (DR) mouse retion STZ treatment upregulated 28246353 556 Mouse MIAT lncRNA hypoxia hypoxic/ischemic injury Neuro2A cells hypoxia treatment lncRNA MIAT was downregulated in oxygen glucose deprivation (OGD)-induced ischemic injury of Neuro2A cells. 30563429 557 Mouse MIAT lncRNA lipopolysaccharide (LPS) pneumonia TC-1 cells lipopolysaccharide (LPS) treatment upregulated 33318298 558 Mouse MIAT lncRNA high glucose (HG) podocyte injury mouse podocytes high glucose (HG) treatment Ablation of lncRNA MIAT mitigates high glucose-stimulated inflammation and apoptosis of podocyte via miR-130a-3p/TLR4 signaling axis. 32972755 559 Mouse MIAT lncRNA collagen rheumatoid arthritis (RA) synovium; myocardial tissues collagen treatment we found that macrophage inflammation induced by LPS could up-regulate lncRNA MIAT expression. 33459112 560 Mouse MIAT lncRNA lipopolysaccharide (LPS) sepsis-induced myocardial injury HL-1 cells lipopolysaccharide (LPS) treatment LncRNA MIAT Promotes Inflammation and Oxidative Stress in Sepsis-Induced Cardiac Injury by Targeting miR-330-5p/TRAF6/NF-¦ÊB Axis 32556678 561 Mouse MIAT lncRNA cinnamaldehyde (CA) ulcerative colitis (UC) colonic tissues Cinnamaldehyde (CA) treatment MIAT was reduced in the DSS-treated mice and was significantly increased after CA treatment. 33341041 562 Mouse MIAT lncRNA hypoxia acute myocardial infarction (AMI) The mouse cardiomyocyte cell line HL-1 cells hypoxia induce "MIAT and EGR2 were subsequently determined to be highly-expressed, whereas miR-10a-5p was found to be poorly-expressed in cardiomyocytes exposed to hypoxia as well as in MI mice using RT-qPCR and Western blot assay." 33819189 563 Mouse MIR143HG lncRNA rosiglitazone diabetic nephropathy (DN) kidney tissues rosiglitazone treatment upregulated 32025515 564 Mouse MIRF lncRNA H2O2 acute myocardial infarction (AMI) primary neonatal mice ventricular cardiomyocytes H2O2 treatment MIRF contributed to cardiomyocyte apoptosis through modulating Bak1 by regulation of miR-26a. 32464547 565 Mouse Mirt1 lncRNA "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)" rheumatoid arthritis (RA) TM3 Leydig cells "phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment" downregulated 33360214 566 Mouse Mirt2 lncRNA lipopolysaccharide (LPS) inflammation C57BL/6 mice lipopolysaccharide (LPS) treatment downregulated 29230038 567 Mouse Mirt2 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) mouse liver tissue high fat diet (HFD) feed downregulated 30898698 568 Mouse Mirt2 lncRNA IFN-¦Ã sj?gren's syndrome (SS) salivary gland epithelial cells (SGECs) interferon gamma (IFN-¦Ã) treatment upregulated 31198060 569 Mouse Mist lncRNA high fat diet (HFD) obesity macrophages high fat diet (HFD) feed LncRNA Mist Is Downregulated in Macrophages From HFD-Fed Obese Mice. 32078363 570 Mouse MM2P lncRNA lipopolysaccharide- and MSU acute gouty arthritis (AGA) RAW 264.7 cells lipopolysaccharide-and MSU treatment downregulated 32705194 571 Mouse MM2P lncRNA lipopolysaccharide (LPS) chondrocyte differentiation mouse bone marrow-derived macrophages lipopolysaccharide (LPS) treatment downregulated 32938906 572 Mouse Morrbid lncRNA hyperglycemia myeloid neoplasms C57/B6 mice hyperglycemia treatment "RNA-Seq revealed that this was due in part to upregulation of proinflammatory pathways, thereby generating a feed-forward loop, including expression of the antiapoptotic, long noncoding RNA (lncRNA) Morrbid." 33090974 573 Mouse MRAK017168 lncRNA subarachnoid hemorrhage (SAH) early brain injury (EBI) brain subarachnoid hemorrhage (SAH) treatment downregulated 25777551 574 Mouse MRAK038897 lncRNA subarachnoid hemorrhage (SAH) early brain injury (EBI) brain subarachnoid hemorrhage (SAH) treatment downregulated 25777551 575 Mouse mrhl lncRNA Wnt3a ligand spermatogenesis Gc1-Spg cells Wnt3a ligand treatment downregulated 25584904 576 Mouse MSTRG.13399.1 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) fetal mice palates "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" upregulated 31961203 577 Mouse MSTRG.1991.1 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) fetal mice palates "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" upregulated 31961203 578 Mouse MSTRG.38487.1 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) fetal mice palates "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" downregulated 31961203 579 Mouse MSTRG.40182.1 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) fetal mice palates "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" downregulated 31961203 580 Mouse MSTRG.51656.1 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) fetal mice palates "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" downregulated 31961203 581 Mouse MSTRG.56310.1 lncRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" cleft palate (CP) fetal mice palates "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" upregulated 31961203 582 Mouse N54010 lncRNA Japanese encephalitis virus (JEV) neuroinflammation mouse brain infect with JEV dysregulated 29033949 583 Mouse NEAT1 lncRNA Iodine-131 (131I) papillary thyroid cancer (PTC) PTC tissues 131I treatment NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo. 30596336 584 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) RAW264.7 macrophages lipopolysaccharide (LPS) treatment upregulated 32388658 585 Mouse NEAT1 lncRNA streptozocin (STZ) Alzheimer's disease (AD) mouse brain tissues streptozocin treatment upregulated 31014193 586 Mouse NEAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) RAW264.7 cells oxidized low-density lipoprotein (ox-LDL) treatment NEAT1 was elevated by ox-LDL in a dose-dependent and time-dependent manner. 30203508 587 Mouse NEAT1 lncRNA insulin-like growth factor binding protein-related protein 1 (IGFBPrP1) autophagy hepatic stellate cell (HSC) IGFBPrP1 treatment upregulated 31610195 588 Mouse NEAT1 lncRNA hypoxia cerebral ischemia injury (CII) mouse brain microvascular endothelial cells (BMECs) oxygen-glucose deprivation (OGD) induce "lncRNA NEAT1 facilitated the survival and angiogenesis of OGD-induced BMECs via targeting miR-377 and promoting the expression of VEGFA, SIRT1, and BCL-XL." 30408478 589 Mouse NEAT1 lncRNA oxygen glucose deprivation (OGD) cerebral ischemia injury (CII) brain microvascular endothelial cells (BMECs) oxygen-glucose deprivation (OGD) treatment Upregulation of lncRNA NEAT1 and downregulated of miR-377 were also observed under OGD conditions 30408478 590 Mouse NEAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury BV2 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 33184298 591 Mouse NEAT1 lncRNA 5-aminolevulinic acid photodynamic therapy(ALA-PDT) colitis colon tissues 5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment downregulated 30385297 592 Mouse NEAT1 lncRNA catalpol diabetic cardiomyopathy (DCM) high glucose (HG) treated mouse cardiomyocytes catalpol treatment Catalpol attenuated HG-induced long noncoding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (Neat1) expression in mouse cardiomyocytes. 31078585 593 Mouse NEAT1 lncRNA glucose diabetic nephropathy (DN) mice mesangial cells glucose treatment upregulated 30515796 594 Mouse NEAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) mice mesangial cells high glucose (HG) treatment upregulated 30549040 595 Mouse NEAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) mice mesangial cells high glucose (HG) treatment NEAT1 was significantly increased in high-glucose-induced mice mesangial cells. 30549040 596 Mouse NEAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) mouse mesangial cells (MMCs) (SV40 MES13 cells) high glucose (HG) treatment upregulated 31933932 597 Mouse NEAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) mouse mesangial cells (MMCs) high glucose (HG) treatment The enrichment of NEAT1 was elevated in MMCs induced by high concentration of glucose. 32096162 598 Mouse NEAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) kidney tissues high glucose (HG) treatment NEAT1 was greatly upregulated in DM rats. 30515796 599 Mouse NEAT1 lncRNA streptozocin (STZ) diabetic nephropathy (DN) mouse mesangial cells streptozocin (STZ) treatment NEAT1 was greatly upregulated in high glucose treated mouse mesangial cells 30515796 600 Mouse NEAT1 lncRNA "insulin, dexamethasone, isobutylmethyxanthine (IBMX)" cell differentiation 3T3-L1 cells IBMX treatment downregulated 25437750 601 Mouse NEAT1 lncRNA high glucose (HG) epithelial-mesenchymal transition (EMT) mice mesangial cells high glucose (HG) treatment upregulated 30549040 602 Mouse NEAT1 lncRNA high glucose (HG) fibrosis mice mesangial cells high glucose (HG) treatment upregulated 30549040 603 Mouse NEAT1 lncRNA herpes simplex virus 1 (HSV-1) herpes simplex virus 1 (HSV-1) infection mouse embryonic fibroblast (MEF) cells infect with HSV-1 upregulated 27783096 604 Mouse NEAT1 lncRNA oxygen glucose deprivation (OGD) hypoxic/ischemic brain damage (HIBD) primary mouse hippocampal neurons cells Oxygen-glucose deprivation (OGD) treatment lncRNA NEAT1 upregulated HOXA1 to alleviate HIBD in mice by binding to miR-339-5p 32163893 605 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) inflammation "Kupffer cells, RAW264.7 cells" lipopolysaccharide (LPS) treatment LPS induces an inflammatory response by upregulating the expression of lncRNA NEAT1. 31344555 606 Mouse NEAT1 lncRNA carbon tetrachloride (CCl4) liver fibrosis mouse carbon tetrachloride (CCl4) treatment upregulated 28864835 607 Mouse NEAT1 lncRNA alcohol nonalcoholic fatty liver disease (NAFLD) AML-12 cells Lieber-DeCarli alcohol treatment NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis 33228663 608 Mouse NEAT1 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) mouse liver tissues high fat diet (HFD) feed upregulated 31484042 609 Mouse NEAT1 lncRNA methionine choline-deficient diet (MCD) nonalcoholic steatohepatitis (NASH) mouse liver tissues methionine-choline-deficient (MCD) treatment Liver tissues from mice fed a methionine-choline-deficient (MCD) diet exhibited increased expression of NEAT1 and PEG3 along with lower miR-129-5p expression. 33574830 610 Mouse NEAT1 lncRNA lithium chloride (LiCl) obesity 3T3L1 cells Lithium chloride (LiCl) treatment downregulated 33288642 611 Mouse NEAT1 lncRNA resveratrol osteoarthritis (OA) mouse chondrocytes resveratrol (Res) treatment "The relative mRNA expression levels of MALAT1 and NF-¦ÊB1 were significantly increased, while treatment with Res partially reversed the mRNA expression levels of MALAT1" 32104302 612 Mouse NEAT1 lncRNA catalpol oxidative stress mouse primary cardiomyocytes catalpol treatment downregulated 31736383 613 Mouse NEAT1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 29287722 614 Mouse NEAT1 lncRNA bovine type II collagen rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) bovine type II collagen induction PBMC-derived exos contributes to RA development with the involvement of the miR-23a/MDM2/SIRT6 axis. 33042992 615 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) Lipopolysaccharide (LPS) treatment LncRNA NEAT1 shuttled by PBMC-derived exos promoted FLS proliferation and inflammation through regulating the MDM2/SIRT6 axis. 33042992 616 Mouse NEAT1 lncRNA methamphetamine (METH) and MK801 schizophrenia (SZ) prefrontal cortex (PFC) methamphetamine (METH) and MK801 treatment downregulated 30243133 617 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis RAW264.7 cells lipopolysaccharide (LPS) treatment upregulated 31812793 618 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis RAW 264.7 lipopolysaccharide (LPS) treatment LncRNA NEAT1 promoted the inflammation and apoptosis while restrained the proliferation of LPS-stimulated RAW 264.7 cells through the miR-370-3p/TSP-1 axis. 31957847 619 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis RAW 264.7 cells; HL-1 cells lipopolysaccharide (LPS) treatment NEAT1 and Irak2 were upregulated in sepsis tissues and LPS-induced RAW 264.7 and HL-1 cells. 32414769 620 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis RAW264.7 cells lipopolysaccharide (LPS) treatment "NEAT1 and POU domain class 2 transcription factor 1 (POU2F1) were highly expressed in LPS-induced septic RAW264.7 cells, opposite to miR-31-5p expression." 33710444 621 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis RAW264.7 cells lipopolysaccharide (LPS) treatment upregulated of NEAT1 level and downregulated of miR-495-3p/miR-211 level could aggravate inflammation in LPS-treated RAW264.7 cells. 31812793 622 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis RAW 264.7 cells; HL-1 cells lipopolysaccharides (LPS) treatment upregulated 34004695 623 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis-induced acute lung injury lung tissues lipopolysaccharide (LPS) treatment upregulated 32089649 624 Mouse NEAT1 lncRNA cecal ligation and puncture (CLP) sepsis-induced brain injury (SIBI) brain tissues cecal ligation and puncture (CLP) treatment upregulated 31115021 625 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis-induced myocardial injury HL-1 cells lipopolysaccharide (LPS) treatment NEAT1 was upregulated in LPS-treated myocardial cells. 32016991 626 Mouse NEAT1 lncRNA lipopolysaccharide (LPS) sepsis-induced myocardial injury mouse heart tissues lipopolysaccharides (LPS) treatment NEAT1 knockdown can improve LPS-induced myocardial injury in mice by inhibiting the TLR2/NF-¦ÊB signaling pathway. 31210324 627 Mouse NEAT1 lncRNA controlled cortical impact (CCI) traumatic brain injury (TBI) C57BL/6J mice controlled cortical impact (CCI) upregulated 28483659 628 Mouse NEAT2 lncRNA methamphetamine (METH) and MK801 schizophrenia (SZ) prefrontal cortex (PFC) methamphetamine (METH) and MK801 treatment downregulated 30243133 629 Mouse NEF lncRNA Hyperoxia lung injury RLE-6TNcells; MLE-12 cells Hyperoxia treatment LncRNA-NEF regulated the hyperoxia-induced injury of lung epithelial cells by FOXA2 33042438 630 Mouse Nespas lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) mouse BV2 cells oxygen-glucose deprivation treatment upregulated 31167620 631 Mouse NKILA lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic neuronal injury murine hippocampal neurons oxygen-glucose deprivation and reoxygenation (OGD/R) treatment OGDR downregulated miR-103 and miR-107 to induce NKILA upregulation in neuronal cells 30007440 632 Mouse NONMMUG002873 lncRNA high fat diet (HFD) cholesterol biosynthesis liver tissues high fat diet (HFD) feed upregulated 30504232 633 Mouse NONMMUG002873 lncRNA palmitic acid (PA) cholesterol biosynthesis AML12 cells palmitic acid (PA) treatment upregulated 30504232 634 Mouse NONMMUG002873 lncRNA WY14643 cholesterol biosynthesis AML12 cells WY14643 treatment upregulated 30504232 635 Mouse NONMMUG027912 lncRNA high fat diet (HFD) cholesterol biosynthesis liver tissues high fat diet (HFD) feed upregulated 30504232 636 Mouse NONMMUG027912 lncRNA palmitic acid (PA) cholesterol biosynthesis AML12 cells palmitic acid (PA) treatment upregulated 30504232 637 Mouse NONMMUG027912 lncRNA WY14643 cholesterol biosynthesis AML12 cells WY14643 treatment upregulated 30504232 638 Mouse NONMMUG043402 lncRNA high fat diet (HFD) cholesterol biosynthesis liver tissues high fat diet (HFD) feed upregulated 30504232 639 Mouse NONMMUG043402 lncRNA palmitic acid (PA) cholesterol biosynthesis AML12 cells palmitic acid (PA) treatment upregulated 30504232 640 Mouse NONMMUG043402 lncRNA WY14643 cholesterol biosynthesis AML12 cells WY14643 treatment upregulated 30504232 641 Mouse NONMMUG043404 lncRNA high fat diet (HFD) cholesterol biosynthesis liver tissues high fat diet (HFD) feed upregulated 30504232 642 Mouse NONMMUG043404 lncRNA palmitic acid (PA) cholesterol biosynthesis AML12 cells palmitic acid (PA) treatment upregulated 30504232 643 Mouse NONMMUG043404 lncRNA WY14643 cholesterol biosynthesis AML12 cells WY14643 treatment upregulated 30504232 644 Mouse NONMMUGO11496 lncRNA toxoplasma gondii (T. gondii) T. gondii induced neurological disorder brain tissues toxoplasma gondii (T. gondii) infection treatment downregulated lncRNA NONMMUG011496 (lncRNA-11496) was identified in the brains of mice infected with T gondii 32499679 645 Mouse NONMMUT004850.2 lncRNA all-trans retinoic acid (ATRA) cleft palate (CP) palate all-trans retinoic acid (ATRA) treatment ?NONMMUT004850.2/NONMMUT024276.2-miR-741-3p/miR-465b-5p-Prkar1¦Á?could potentially serve as an important regulatory mechanism of palatal fusion in the development of the cleft palate. 32042778 646 Mouse NONMMUT005697 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed upregulated 29986645 647 Mouse NONMMUT016106 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed upregulated 29986645 648 Mouse NONMMUT021632 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) placenta high fat diet (HFD) feed downregulated 29986645 649 Mouse NONMMUT022554 lncRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) fibrotic lung tissues of mice and pulmonary fibroblasts TGF-¦Â1 treatment lncRNA NONMMUT022554 was increased in fibrotic lung tissues of mice and pulmonary fibroblasts exposed to transforming growth factor (TGF)-¦Â1 29952219 650 Mouse NONMMUT024276.2 lncRNA all-trans retinoic acid (ATRA) cleft palate (CP) palate all-trans retinoic acid (ATRA) treatment ?NONMMUT004850.2/NONMMUT024276.2-miR-741-3p/miR-465b-5p-Prkar1¦Á?could potentially serve as an important regulatory mechanism of palatal fusion in the development of the cleft palate. 32042778 651 Mouse NONMMUT033416.2 lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment upregulated 31833538 652 Mouse NONMMUT040834 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed upregulated 29986645 653 Mouse NONMMUT063872 lncRNA codonopsis pilosula anti-aging effect of Codonopsis pilosula lung tissues codonopsis pilosula treatment NONMMUT063872 was significantly increased in the model group compared with the control group and was significantly decreased in the high-dose Codonopsis pilosula treatment (HC) group compared with the model group. 32049955 654 Mouse NONMMUT065582 lncRNA bleomycin (BLM) idiopathic pulmonary fibrosis (IPF) lung fibrosis tissues bleomycin (BLM) treatment NONMMUT065582 is upregulated in the lungs of mice. 30025992 655 Mouse NONMMUT065582 lncRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) primary mouse lung fibroblasts TGF-¦Â1 treatment NONMMUT065582 is upregulated in fibrotic lung fibroblasts 30025992 656 Mouse NONMMUT068202 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) placenta high fat diet (HFD) feed upregulated 29986645 657 Mouse NONMMUT068206 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) placenta high fat diet (HFD) feed upregulated 29986645 658 Mouse NONMMUT068207 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) placenta high fat diet (HFD) feed upregulated 29986645 659 Mouse NONMMUT073434 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) placenta high fat diet (HFD) feed upregulated 29986645 660 Mouse NONMMUT080010.1 lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment downregulated 31833538 661 Mouse NONMMUT124495.1 lncRNA palmitic acid (PA) insulin resistance (IR) C2C12 cells palmitic acid treatment upregulated 31833538 662 Mouse NORAD lncRNA high glucose (HG) diabetic nephropathy (DN) SV40-MES-13?cells high glucose (HG) treatment upregulated 31630796 663 Mouse NR_002854.2 lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment downregulated 32626785 664 Mouse NR_015555.1 lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment downregulated 32626785 665 Mouse NR_024118 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) ATDC5 cell line lipopolysaccharide (LPS) treatment downregulated 31485657 666 Mouse NR_024118 lncRNA shikonin rheumatoid arthritis (RA) RA synovial fibroblasts Shikonin treatment upregulated 26640499 667 Mouse NR_027710 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment NR_027710 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 668 Mouse NR_027710 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment downregulated 29115403 669 Mouse NR_027710 lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment NR_027710 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 670 Mouse NR_030715 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment NR_030715 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 671 Mouse NR_030715 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment downregulated 29115403 672 Mouse NR_030715 lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment NR_030715 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 673 Mouse NR_030777 lncRNA paraquat (PQ) parkinson's disease (PD) Neuro-2a; N2a cells paraquat (PQ) treatment NR_030777 Alleviates Paraquat-Induced Neurotoxicity by Regulating Zfp326 and Cpne5 32735315 674 Mouse NRON lncRNA angiotensin II (Ang II) atrial fibrosis mouse primary cultured atrial myocytes angiotensin II (Ang II) treatment LncRNA NRON suppresses inflammatory response in Ang II-treated atrial myocytes 31693733 675 Mouse NRON lncRNA angiotensin II (Ang II) macrophage polarization RAW264.7 macrophages angiotensin II (Ang II) treatment NRON promotes M2 macrophage polarization and alleviates atrial fibrosis through suppressing exosomal miR-23a derived from atrial myocytes. 33246743 676 Mouse Gm15154-201 lncRNA fasciola gigantica excretory/secretory products (ESP) macrophage activation and polarization M2 macrophages fasciola gigantica excretory/secretory products (ESP) treatment upregulated 29794463 677 Mouse Gm15765-201 lncRNA fasciola gigantica excretory/secretory products (ESP) macrophage activation and polarization M2 macrophages fasciola gigantica excretory/secretory products (ESP) treatment upregulated 29794463 678 Mouse Ube4bos2-201 lncRNA fasciola gigantica excretory/secretory products (ESP) macrophage activation and polarization M2 macrophages fasciola gigantica excretory/secretory products (ESP) treatment upregulated 29794463 679 Mouse Gm17233-201 lncRNA fasciola gigantica excretory/secretory products (ESP) macrophage activation and polarization M2 macrophages fasciola gigantica excretory/secretory products (ESP) treatment upregulated 29794463 680 Mouse NUNMMUT016103 lncRNA sodium butyrate (NaB) asthma nasal mucosa sodium butyrate (NaB) treatment NUNMMUT016103 was downregulated after sodium butyrate (NaB) treatment. 32124940 681 Mouse OAD lncRNA bone morphogenetic protein 2 (BMP2) osteoblastic differentiation "C3H10T1/2 mesenchymal stem cells , MC3T3-E1 preosteoblast cells" bone morphogenetic protein 2 (BMP2) treatment Lnc-OAD expression was increased during BMP-2-induced osteoblast differentiation in C3H10T1/2 mesenchymal stem cells and MC3T3-E1 preosteoblast cells. 33816629 682 Mouse Obox4-ps35 lncRNA triptolide (TPL) reproductive toxicity GC2 cells triptolide (TPL) treatment Obox4-ps35 knock-out aggravated triptonide-induced cytotoxicity by decreasing cell survival and increasing apoptosis and autophagy rates 33045310 683 Mouse ODSM lncRNA mechanical unloading bone loss MC3T3-E1 cells Mechanical unloading treatment Overexpression of the lncRNA ODSM partially reduces apoptosis and promotes differentiation in MC3T3-E1 cells under MG unloading conditions. 32071307 684 Mouse OGD-1006 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) primary brain microvascular endothelial cells (bEnd.3) oxygen-glucose deprivation (OGD) treatment LncOGD-1006 might act as a ceRNA to inhibit apoptosis in bEnd3 cells by targeting miR-184-5p/CAAP1 pathway 33336752 685 Mouse OIP5-AS1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) BV2 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 33516048 686 Mouse OIP5-AS1 lncRNA IL-1¦Â osteoarthritis (OA) ATDC5 cells IL-1¦Â treatment OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models. 32037864 687 Mouse Oprm1 lncRNA hypoxia ischemic stroke (IS) mouse brain tissues middle cerebral artery occlusion (MCAO) Infarct size was distinctly decreased in the lncRNA Oprm1-overexpression group. 31187646 688 Mouse Oprm1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) N2a cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment Overexpression of lncRNA Oprm1 alleviated the apoptosis induced by oxygen-glucose deprivation and significantly reduced cleaved caspase-3 levels 31187646 689 Mouse linc-p21 lncRNA hypoxia acute respiratory distress syndrome (ARDS) mouse mesenchymal stem cells (MSCs) hypoxia treatment MSCs induced by hypoxic preconditioning evoked an increase in expression of LincRNA-p21. 30359325 690 Mouse linc-p21 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) lung fibroblasts lipopolysaccharide (LPS) treatment upregulated 27392907 691 Mouse linc-p21 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) mouse alveolar macrophages (AMs); MH-S cells lipopolysaccharide (LPS) treatment Elevated lincRNA-p21 levels were observed in both LPS-induced ARDS mice and LPS-treated MH-S cells. 32362153 692 Mouse linc-p21 lncRNA high fat diet (HFD) atherosclerosis (AS) vascular smooth muscle cell (VSMC) high fat diet (HFD) feed "p53-dependent lincRNA-p21 expression downregulated miR-17-5p, whichconsequently protecting against AS progression via SIRT7 elevation." 33169349 693 Mouse linc-p21 lncRNA doxorubicin (DOX) cardiotoxicity HL-1 murine cardiomyocytes2 doxorubicin treatment upregulated 29207090 694 Mouse linc-p21 lncRNA furan cell proliferation mice liver cells Furan treatment lncRNAs are transcriptional targets of furan exposures associated with levels of furan that are cytotoxic and induce cell proliferation. 23853263 695 Mouse linc-p21 lncRNA doxorubicin (DOX) doxorubicin (DOX)-induced cardiotoxicity HL-1 cells doxorubicin (Dox) treatment p21 was highly expressed in Dox-treated HL-1 murine cardiomyocytes. 29207090 696 Mouse linc-p21 lncRNA salvianolic acid B (Sal B) hepatic stellate cell (HSC) activation HSCs isolated from C57BL/6J mice treat with Sal B treatment upregulated 28391277 697 Mouse linc-p21 lncRNA ¦Ã-rays irradiation-induced tumors bone marrow (BM) low-power long-term ¦Ã-irradiation downregulated 32483710 698 Mouse linc-p21 lncRNA carbon tetrachloride (CCl4) liver fibrosis liver tissues carbon tetrachloride (CCl4) treatment upregulated in hepatocytes 28592847 699 Mouse linc-p21 lncRNA thymosin ¦Â4 (T¦Â4) liver damage hepatic tissues ; hepatic stellate cells (HSCs) Thymosin ¦Â4 (T¦Â4) treatment T¦Â4 inhibited the increased expression of lincRNA-p21 by transfection of Ad-p21 32649978 700 Mouse linc-p21 lncRNA lipopolysaccharide (LPS) neuropathic pain (NP) BV2 cells ?lipopolysaccharide (LPS) treatment "In this study, we found that lncRNA p21 and tumor necrosis factor alpha-induced protein 1 (Tnfaip1) expression were upregulated and miR-181b expression was downregulated in lipopolysaccharide (LPS)-induced and activated BV-2 microglia" 33774143 701 Mouse linc-p21 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 30671473 702 Mouse linc-p21 lncRNA astragaloside IV (AS-IV) parkinson's disease (PD) MN9D cells; brain tissues astragaloside IV (AS-IV) treatment AS-IV inhibit the expression of lincRNA-p21. in PD mice and PD cells. 32511947 703 Mouse linc-p21 lncRNA ultraviolet (UV) irradiation skin cancer keratinocytes UVB-irradiated treatment lincRNA-p21 is highly inducible by UVB 25789975 704 Mouse PADNA lncRNA bupivacaine bupivacaine-induced neurotoxicity mouse DRG neurons bupivacaine treatment lincRNA PADNA/miR-194/FBXW7 axis plays an important role in the neurotoxicity process. 32791990 705 Mouse PAX8-AS1 lncRNA high glucose (HG) diabetic nephropathy (DN) MPC5 cells high glucose (HG) treatment Inhibition of lncRNA-PAX8-AS1-N directly associated with VEGF/TGF-¦Â1/8-OhdG enhances podocyte apoptosis in diabetic nephropathy. 32633379 706 Mouse PCAI lncRNA lipopolysaccharide (LPS) postoperative cognitive dysfunction (POCD) BV-2 cells lipopolysaccharide (LPS) treatment Overexpression of lncRNA PCAI can promote the cell death and inflammation response induced by LPS. 32247002 707 Mouse PCAT29 lncRNA silica lung fibrosis pulmonary fibroblasts silica treatment lncRNAPCAT29 were downregulated within interstitial lung cells from mice with silica-induced pulmonary fibrosis. 29620190 708 Mouse PCFL lncRNA TGF-¦Â1 cardiac fibrosis mouse cardiac fibroblasts (CFs) TGF-¦Â1 treatment upregulated 31220469 709 Mouse PEG10 lncRNA phenylephrine (PE) cardiac hypertrophy mouse primary cardiomyocytes phenylephrine (PE) treatment upregulated 31389601 710 Mouse PFAR lncRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) mouse primary lung fibroblasts TGF-¦Â1 treatment silencing PFAR attenuated TGF-¦Â1 induced fibrogenesis in primary lung fibroblasts 31273058 711 Mouse PGC1¦Â-OT1 lncRNA adipogenesis medium adipocyte and osteoblast differentiation ST2 or C3H10T1/2 cells "adipogenic medium ((¦Á-MEM containing 10% FBS, 0.5 ¦ÌM dexamethasone, 0.25 mM methylisobutylxanthine, 5 ¦Ìg/ml insulin, and 50 ¦ÌM indomethacin) treatment" downregulated 30728459 712 Mouse PGC1¦Â-OT1 lncRNA osteogenic differentiation medium adipogenesis ST2 or MC3T3-E1 cells "osteogenic medium (¦Á-MEM containing 10% FBS, 50 ¦Ìg/ml ascorbic acid, and 5 mM ¦Â-glycerophosphate) treatment" upregulated 30728459 713 Mouse Pirb lncRNA tanshinone IIA (Tan IIA) atherosclerosis (AS) RAW 264.7 cells Tanshinone IIA (Tan) treatment downregulated 32337768 714 Mouse Plscr4 lncRNA angiotensin II (Ang II) cardiac hypertrophy cardiomyocytes angiotensin II (Ang II) treatment lncRNA Plscr4 was upregulated in hypertrophic mice hearts and in angiotensin II (Ang II)-treated cardiomyocytes. 29499950 715 Mouse Plscr4 lncRNA angiotensin II (Ang II) cardiac hypertrophy mouse cardiomyocytes angiotensin II (Ang II) treatment upregulated 29499950 716 Mouse PMS2L2 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) ATDC5 cells lipopolysaccharide (LPS) treatment PMS2L2 expression was downregulated following LPS stimulation. 30550887 717 Mouse PMS2L2 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) mouse chondrogenic ATDC5 cells lipopolysaccharide (LPS) treatment "PMS2L2 expression was downregulated following LPS stimulation. PMS2L2 protected ATDC5 cells against LPS-induced injury by increasing cell viability, decreasing apoptosis, and repressing the release of pro-inflammatory factors." 30550887 718 Mouse PRINS lncRNA hypoxia acute kidney injury (AKI) renal tubular cells hypoxia treatment upregulated 26725683 719 Mouse PRINS lncRNA high glucose (HG) diabetic nephropathy (DN) mouse podocyte cells high glucose (HG) treatment upregulated 30936994 720 Mouse PRNCR1 lncRNA cisplatin (DDP) acute kidney injury (AKI) kidney tissues cisplatin treatment downregulated 33647908 721 Mouse PRNCR1 lncRNA lipopolysaccharide (LPS) pulmonary vascular endothelial cell (PVEC) injury human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment "PRNCR1 and TLR4 levels were significantly upregulated in LPS-treated PVEC, both in vivo and in vitro, while miR-330-5p were downregulated. Inhibiting PRNCR1 or overexpressing miR-330-5p markedly attenuated LPS-induced PVEC injury." 33049095 722 Mouse Psmd11 lncRNA pilocarpine epilepsy hippocampal tissues pilocarpine treatment "Psmd11 was upregulated by Peg13 at a miR-490-3p dependent way, thus inactivating the Wnt/¦Â-catenin pathway and alleviating epilepsy course in mice" 33437373 723 Mouse PTPRE-AS1 lncRNA IL-4 macrophage activation Mouse bone marrow-derived macrophages (BMDMs) IL-4 treatment upregulated 31844669 724 Mouse PU.1-AS lncRNA arsenite arsenite-induced abnormal lipid metabolism liver tissues arsenic exposure upregulated 31471020 725 Mouse PVT1 lncRNA lipopolysaccharide (LPS) sepsis myocardial tissue and heart infiltrating macrophages lipopolysaccharide (LPS) treatment upregulated 33840587 726 Mouse PVT1 lncRNA angiotensin II (Ang II) abdominal aortic aneurysm (AAA) Apolipoprotein E-deficient (ApoE-/-) male mice abdominal aortic tissues angiotensin II (Ang II) treatment upregulated 30726659 727 Mouse PVT1 lncRNA hypoxia activation of hepatic stellate cells (HSCs) hepatic stellate cells (HSCs) hypoxia treatment Hypoxia induces the activation of hepatic stellate cells through the PVT1-miR-152-ATG14 signaling pathway. 31893334 728 Mouse PVT1 lncRNA ozone (O3) asthma CD4+ T cells and ASMCs ozone treatment lncRNA PVT1-miR-15a-5p/miR-29c-3p-PI3K-Akt-mTOR axis was implicated in ozone-induced asthma development by promoting ASMC proliferation and Th1/Th2 imbalance 33223504 729 Mouse PVT1 lncRNA angiotensin II (Ang II) atrial fibrosis mouse atrial tissues angiotensin II (Ang II) treatment "upregulated, PVT1 knockdown attenuated the Ang-II-induced mouse atrial fibrosis." 30894138 730 Mouse PVT1 lncRNA high glucose (HG) diabetic nephropathy (DN) Mouse podocyte clone 5 (MPC5) podocytes and primary podocytes high glucose (HG) treatment upregulated 31371698 731 Mouse PVT1 lncRNA streptozocin (STZ) diabetic nephropathy (DN) kidney tissues streptozotocin treatment upregulated 31371698 732 Mouse PVT1 lncRNA streptozocin (STZ) diabetic osteoarthritis (OA) cartilage tissues streptozotocin (STZ) treatment "PVT1 expression was significantly increased, whereas miR-146a was markedly decreased in diabetic OA mice than in non-diabetic OA and control" 33569722 733 Mouse PVT1 lncRNA hypoxia hepatic stellate cell (HSC) activation primary mouse HSCs hypoxia induce upregulated 31893334 734 Mouse PVT1 lncRNA hypoxia immunosuppression MDSCs;granulocytic MDSCs (G-MDSCs) O2 < 0.1 induce upregulated 30925926 735 Mouse PVT1 lncRNA IL-6 and granulocyte-macrophage colony stimulating factor (GM-CSF) immunosuppression MDSCs or granulocytic MDSCs (G-MDSCs) ?IL-6 and GM-CSF induce treatment upregulated 30925926 736 Mouse PVT1 lncRNA unmethylated cytosine followed by guanine (CpG ODN) macrophage activation RAW264.7 cells unmethylated cytosine followed by guanine (CpG ODN) treatment upregulated 32626785 737 Mouse Rian lncRNA oxygen glucose deprivation (OGD) ischemia/reperfusion (I/R) injury N2a cells oxygen-glucose deprivation treatment Overexpression of long non-coding RNA Rian attenuates cell apoptosis from cerebral ischemia-reperfusion injury via Rian/miR-144-3p/GATA3 signaling 33294587 738 Mouse RMRP lncRNA ovalbumin (OVA) asthma lung tissues ovalbumin (OVA) treatment "The expression of RMRP and CCL2 was elevated, while miR-206 was reduced in OVA-induced mice." 33511814 739 Mouse RMRP lncRNA valproic acid (VPA) ischemic stroke (IS) BV2 cells valproate (VPA) treatment Valproate improves middle cerebral artery occlusion-induced ischemic cerebral disorders in mice and oxygen-glucose deprivation-induced injuries in microglia by modulating RMRP/PI3K/Akt axis 32745656 740 Mouse RMRP lncRNA lipopolysaccharide (LPS) myocardial dysfunction cardiomyocytes lipopolysaccharide (LPS) treatment The lncRNA RMRP axis acts as a sponge for miR-1-5p. RMRP inhibits LPS-induced apoptosis of cardiomyocytes and mitochondrial damage by suppressing the post-transcriptional regulatory function of miR-1-5p on HSPA4. 31900829 741 Mouse Rmst lncRNA oxygen glucose deprivation (OGD) hypoxic/ischemic brain damage (HIBD) brain microvascular endothelial cells (BMECs) oxygen-glucose deprivation (OGD) treatment OGD exposure augmented the level of Rmst while reduced the expression of miR-150 in bEnd3 cells 32728986 742 Mouse RMST lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) primary hippocampal neuron oxygen-glucose deprivation (OGD) treatment upregulated 29258823 743 Mouse RMST lncRNA hypoxia ischemic stroke (IS) hippocampal neuron tissues middle cerebral artery occlusion (MCAO) treatment upregulated 29258823 744 Mouse RMST lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) Mouse microglial BV2 cells oxygen-glucose deprivation (OGD) induce treatment upregulated 31329361 745 Mouse RMST lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) HT-22?hippocampal neuron cells oxygen-glucose-deprivation (OGD) treatment RMST was highly expressed in OGD-treated HT-22?hippocampal neuron cells 31852624 746 Mouse RMST lncRNA oxygen glucose deprivation (OGD) neuron apoptosis HT-22 hippocampal neuron cell oxygen-glucose deprivation (OGD) treatment RMST/hnRNPK/p53/miR-107/Bcl2l2 axis plays an important role in regulating neuronal apoptosis 31852624 747 Mouse Rmst lncRNA bone morphogenetic protein 9 (BMP9) osteogenesis The conditionally immortalized mouse multipotent adipose-derived cells iMADs bone morphogenetic protein 9 (BMP9) treatment upregulated 31825894 748 Mouse RNCR2 lncRNA oxygen pathological neovascularization mouse ocular neovascularization exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment dysregulated 24623407 749 Mouse RNCR3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) plasma oxidized low-density lipoprotein (ox-LDL) treatment upregulated 27253412 750 Mouse RNCR3 lncRNA high glucose (HG) retinal microvascular abnormality RF/6A cells high glucose treatment upregulated 27876564 751 Mouse RNCR4 lncRNA streptozocin (STZ) diabetic retinopathy (DR) C57BL/6 mice intraperitoneal injection of STZ(77 70 mg/kg B.W.) treatment upregulated 27876564 752 Mouse ROR lncRNA hypoxia/reoxygenation (H/R) hypoxia/reoxygenation (H/R) injury H9C2 cells hypoxia/reoxygenation (H/R) treatment lncRNA ROR sponges miR-138 to aggravate H/R-induced myocardial cell injury by upregulating the expression of Mst1. 32240614 753 Mouse RP23-430H21.1 lncRNA propofol (PPF) propofol-induced neurotoxicity hippocampus propofol treatment downregulated 29628875 754 Mouse Rpa lncRNA lead (Pb) lead (Pb) toxicity mouse neuroblastoma N2a cells PbAc treatment upregulated 27604105 755 Mouse Rps4l lncRNA hypoxia pulmonary hypertension (PH) arteries; pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment Rps4l expression was significantly reduced in PH-model mice and hypoxic PASMCs. 32772647 756 Mouse RUNXOR lncRNA cytarabine (Ara-C) leukemia Leuke mic K562 cells exposure to a low dose of the antileu_x0002_kemic drug by Ara-C treatment upregulated 24752773 757 Mouse SETD5-AS1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) N2a cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment SETD5-AS1 was highly expressed in the ischemia-reperfusion injury model 30280788 758 Mouse SHNG16 lncRNA oxygen glucose deprivation (OGD) neuronal cell injury HT22 hippocampal neurons oxygen-glucose deprivation (OGD) treatment downregulated 32323054 759 Mouse SHNG16 lncRNA dexamethasone (DEX) oxygen-glucose deprivation (OGD) induced neuron damage HT22 hippocampal neurons dexamethasone (Dex) treatment upregulated 32323054 760 Mouse SIAH1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 29217406 761 Mouse Six3OS lncRNA oxygen pathological neovascularization mouse ocular neovascularization exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment dysregulated 24623407 762 Mouse Smad7 lncRNA TGF-¦Â breast cancer mouse mammary gland epithelial cells and breast cancer cell lines mouse mammary gland epithelial cells continuously with TGF-¦Â treatment upregulation 24863656 763 Mouse SNHG1 lncRNA oxygen glucose deprivation (OGD) brain vascular dysfunction brain microvascular endothelial cell (BMEC) oxygen-glucose deprivation (OGD) treatment SNHG1 and miR-338 were upregulated in OGD induced BMEC. 30414401 764 Mouse SNHG1 lncRNA phenylephrine (PE) cardiac hypertrophy neonatal mouse cardiomyocytes phenylephrine [PE] treatment downregulated 31889385 765 Mouse SNHG1 lncRNA hypoxia ischemic stroke (IS) Mice primary brain microvascular endothelial cells (BMEC) oxygen/glucose-deprived (OGD)?treatment upregulated 30414401 766 Mouse Snhg1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) brain microvascular endothelial cells (BMECs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment OGD/R induces the expression of Snhg1 29883549 767 Mouse SNHG1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) bEnd3 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment SNHG1 and salt-induced kinase 1 (SIK1) were upregulated in oxygen-glucose deprivation/reperfusion (OGD/R)-induced bEnd3 cells 33677804 768 Mouse SNHG1 lncRNA sevoflurane (SEV) neurotoxicity HT22 cells Sevoflurane treatment upregulated 32150149 769 Mouse SNHG1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) MN9D dopaminergic neurons N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 31499060 770 Mouse SNHG1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) midbrain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 29217406 771 Mouse SNHG1 lncRNA lipopolysaccharide (LPS) parkinson's disease (PD) BV2 cells lipopolysaccharide (LPS) treatment "Snhg1 expression was elevated, whereas miR-7 reduced in LPS-induced BV2 cells." 30031125 772 Mouse SNHG12 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) brain microvascular endothelial cell injury brain microvascular endothelial cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment SNHG12 levels in brain microvascular endothelial cells increased with respect to OGD exposure time 30233065 773 Mouse SNHG12 lncRNA hypoxia cerebral ischemia/reperfusion (I/R) injury brain tissues middle cerebral artery occlusion/reperfusion (MCAO/R) injury upregulated 31056262 774 Mouse SNHG12 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia injury (CII) primary neurons oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31469718 775 Mouse SNHG12 lncRNA hypoxia ischemic stroke (IS) primary neuronal cells and N2a cells oxygen-glucose deprivation (OGD) treatment upregulated 30144542 776 Mouse SNHG12 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) primary neuronal cells and N2a cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment SNHG12 was upregulated in primary neuronal cells and N2a cells and peaked at 12?h and 24?h after OGD/R treatment 30144542 777 Mouse SNHG12 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) mouse brain microvascular endothelial (bEnd.3) cells oxygen-glucose deprivation (OGD) treatment "SNHG12 expression was elevated, whereas miR-150 reduced in OGD-exposed bEnd.3 cells." 30193860 778 Mouse SNHG12 lncRNA 2/3 partial hepatectomy (PH) liver regeneration mouse liver tissues 2/3 partial hepatectomy (PH) treatment upregulated 31894329 779 Mouse SNHG12 lncRNA hepatocyte growth factor (HGF) liver regeneration primary mouse hepatocytes hepatocyte growth factor (HGF) treatment The expression of SNHG12 was also increased in normal liver cell lines treated with different concentrations of hepatocyte growth factor (HGF). 31894329 780 Mouse SNHG12 lncRNA hepatocyte growth factor (HGF) liver regeneration Mouse primary hepatocytes and e NCTC 1469 and BNL CL.2 mouse hepatocyte cell lines hepatocyte growth factor (HGF) (PH) treatment upregulated 31894329 781 Mouse SNHG12 lncRNA angiotensin II (Ang II) vascular endothelial injury aortic primary endothelial cells angiotensin II (Ang II) treatment "As a result, LncRNA SNHG12 was downregulated in aortic primary ECs isolated from Ang II-induced hypertensive mice and 1 kidney/deoxycorticosterone acetate/salt-induced hypertensive mice." 33464650 782 Mouse SNHG14 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) mouse alveolar macrophages (MH-S) and lung tissues lipopolysaccharide (LPS) treatment lncRNA SNHG14 silencing alleviated inflammation in LPS-induced ALI through miR-34c-3p-mediated inhibition of WISP1. 31660971 783 Mouse SNHG14 lncRNA angiotensin II (Ang II) cardiac hypertrophy primary cardiomyocytes (PCM) angiotensin II (Ang II) treatment upregulated 32436661 784 Mouse SNHG14 lncRNA oxygen glucose deprivation (OGD) cerebral infarction (CI) BV-2 cells oxygen/glucose deprivation (OGD) treatment upregulated 28215748 785 Mouse SNHG14 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury HT22 (mouse hippocampal neuronal cells) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment lncRNA SNHG14 promotes OGD/R-induced neuron injury by inducing excessive mitophagy via miR-182-5p/BINP3 axis in HT22 mouse hippocampal neuronal cells 32912324 786 Mouse SNHG14 lncRNA rotenone (ROT) parkinson's disease (PD) mouse MN9D cells rotenone treatment "In MN9D cells, the rotenone treatment (1¦Ìmol/L) enhanced the binding between transcriptional factor SP-1 and SNHG14 promoter, thus promoting SNHG14 expression" 31683259 787 Mouse SNHG14 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) midbrain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 33071725 788 Mouse SNHG14 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) primary Neuron 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 33071725 789 Mouse SNHG14 lncRNA dexmedetomidine (DEX) spinal cord ischemia/reperfusion injury (SCII) primary microglia dexamethasone (DEX) treatment DEX inhibited microglial activation and downregulated SNHG14 expression in SCIRI mice and oxygen and glucose deprivation/reoxygenation (OGD/R)-treated primary microglia. 33045891 790 Mouse SNHG15 lncRNA streptozocin (STZ) diabetes mellitus (DM) gastrocnemius tissues; endothelial cells isolated from gastrocnemius tissues Streptozocin (STZ) treatment downregulated 33636173 791 Mouse SNHG15 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) HT22 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment "The SNHG15 and STAT1/NF-¦ÊB pathways were both distinctly upregulated, while miR-302a-3p was notably downregulated in the ischemia cortex" 33779086 792 Mouse SNHG15 lncRNA oxygen glucose deprivation (OGD) neuronal cell injury Neuro-2a (N2a) oxygen-glucose deprivation (OGD) treatment "Silencing of SNHG15 led to CXCL13 upregulation through sequestering miR-18a and the following ERK/MEK activation, thus enhancing viability while reducing apoptosis of N2a cells." 32862188 793 Mouse SNHG16 lncRNA bleomycin (BLM) idiopathic pulmonary fibrosis (IPF) pulmonary fbrotic tissues bleomycin (BLM) treatment upregulated 33549106 794 Mouse SNHG16 lncRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) Primary mouse lung fbroblasts TGF-¦Â1 treatment downregulated 33549106 795 Mouse SNHG16 lncRNA high glucose (HG) diabetic nephropathy (DN) mesangial cells high glucose (HG) treatment LncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy. 32504027 796 Mouse SNHG16 lncRNA H2O2 ischemia/reperfusion (I/R) injury cardiomyocytes H2O2 treatment NHG16 accelerates the proliferative ability of cardiomyocytes following IRI by negatively regulating miRNA-770-5p. 32855691 797 Mouse SNHG16 lncRNA high glucose (HG) podocyte injury MPC5 cells high glucose (HG) treatment SNHG16 was significantly upregulated in HG-induced podocytes 33116706 798 Mouse SNHG17 lncRNA high glucose (HG) diabetic nephropathy (DN) MPC5 high glucose (HG) treatment lncRNA SNHG17 knockdown promotes Parkin-dependent mitophagy and reduces apoptosis of podocytes through regulating the degradation of Mst1. 32627655 799 Mouse SNHG20 lncRNA diethylnitrosamine (DEN) nonalcoholic fatty liver disease (NAFLD) liver tissues diethyl nitrosamine (DEN) treatment upregulated 31408278 800 Mouse SNHG20 lncRNA high fat diet (HFD) nonalcoholic fatty liver disease (NAFLD) liver tissues high fat diet (HFD) feed downregulated 31408278 801 Mouse SNHG3 lncRNA oxygen glucose deprivation (OGD) brain ischemia-reperfusion (I/R) injury N2a cells oxygen and glucose deprivation (OGD) treatment upregulated 32860611 802 Mouse SNHG3 lncRNA hypoxia hypoxic/ischemic brain damage (HIBD) primary hippocampal cells hypoxia induce downregulated 31751562 803 Mouse SNHG3 lncRNA hypoxic/ischemic hypoxic/ischemic brain damage (HIBD) primary hippocampal cells hypoxic/ischemic stress "Snhg3 acted as the sponge of miR-196 in the hippocampal cells by regulating the expression of miR-196 target genes, XIAP and CAAP1." 31751562 804 Mouse SNHG5 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) lung tissues lipopolysaccharide (LPS) treatment "SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice." 33170429 805 Mouse SNHG5 lncRNA 5-aminolevulinic acid photodynamic therapy(ALA-PDT) colitis colon tissues 5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment downregulated 30385297 806 Mouse SNHG6 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) primary neuronal cells oxygen glucose deprivation (OGD)-induce treatment upregulated 31334597 807 Mouse SNHG7 lncRNA carbon tetrachloride (CCl4) liver fibrosis primary hepatic stellate cell (HSC) CCl4 treatment upregulated 31272073 808 Mouse SNHG7 lncRNA TGF-¦Â liver fibrosis primary hepatic stellate cells (HSCs) TGF-¦Â treatment SNHG7 was signally increased in liver tissue and HSCs of liver fibrosis model of mice 32893175 809 Mouse SNHG8 lncRNA hypoxia ischemic brain injury ?HT22 cells and hippocampal tissues hypoxia induce downregulated 31165722 810 Mouse SNHG8 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) brain microvascular endothelial cell (BMEC) oxygen-glucose deprivation (OGD) treatment downregulated 33491845 811 Mouse sONE lncRNA high salt diet hypertension systolic blood pressure high salt diet treatment downregulated 26261587 812 Mouse SOX2OT lncRNA H2O2 abdominal aortic aneurysm (AAA) vascular smooth muscle cell (VSMC) oxidative stress Silencing of long non-coding RNA Sox2ot inhibits oxidative stress and inflammation of vascular smooth muscle cells in abdominal aortic aneurysm via microRNA-145-mediated Egr1 inhibition. 32629426 813 Mouse SOX2OT lncRNA H2O2 diabetes-induced retinal neurodegeneration retinal ganglion cell (RGC) H2O2 treatment upregulated 27193103 814 Mouse SOX2OT lncRNA high glucose (HG) diabetes-induced retinal neurodegeneration retinal ganglion cell (RGC) high glucose (HG) treatment upregulated 27193103 815 Mouse SOX2OT lncRNA streptozocin (STZ) diabetes-induced retinal neurodegeneration renal tissues streptozocin (STZ) treatment downregulated 27193103 816 Mouse SOX2OT lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87 cells; U251 cells temozolomide (TMZ) treatment "LncRNA SOX2OT inhibited cell apoptosis, promoted cell proliferation, and TMZ resistance by upregulating SOX2 expression, which activated the Wnt5a/¦Â-catenin signaling pathway" 32439916 817 Mouse SOX2OT lncRNA isoprenaline cardiac fibrosis cardiac fibroblasts (CFs) isoprenaline (ISO) tteatment LncRNA SOX2OT/Smad3 feedback loop promotes myocardial fibrosis in heart failure. 32959533 818 Mouse SOX2OT lncRNA lipopolysaccharide (LPS) sepsis-induced myocardial injury mouse heart tissues lipopolysaccharide (LPS) treatment upregulated 31618067 819 Mouse Spry1 lncRNA TGF-¦Â cell proliferation NMuMG mammary epithelial cells TGF-¦Â treatment downregulated 28186499 820 Mouse SRA lncRNA dehydroepiandrosterone (DHEA) polycystic ovarian syndrome (PCOS) ovary tissues DHEA treatment Silencing of lncRNA Steroid Receptor RNA Activator (SRA) attenuates polycystic ovary syndrome (PCOS) in mice. 30391287 821 Mouse SRA lncRNA dehydroepiandrosterone (DHEA) polycystic ovarian syndrome (PCOS) mouse primary granulosa cell culture DHEA treatment Silencing of lncRNA Steroid Receptor RNA Activator (SRA) attenuates polycystic ovary syndrome (PCOS) in mice. 30391287 822 Mouse SRA lncRNA dehydroepiandrosterone (DHEA) polycystic ovarian syndrome (PCOS) ovary DHEA treatment upregulated 30391287 823 Mouse SRAs lncRNA IL-2 type 1 diabetes mellitus (T1DM) MIN6 ¦Â-cells IL-2 treatment downregulated 33572095 824 Mouse SYNE1-AS1 lncRNA angiotensin II (Ang II) cardiac hypertrophy Cardiomyocytes were isolated from the neonatal mouse angiotensin II (Ang II) treatment the hypertrophic responses were attenuated by SYNE1-AS1 knockdown. 30652310 825 Mouse TCONS_00019174 lncRNA chronic ultra-mild stress depression hippocampus chronic ultra-mild stress treatment mice exposed to chronic ultra-mild stress displayed apparent depression-like behaviors and decreased expression of long non-coding RNA TCONS_00019174 in hippocampus. 29036835 826 Mouse THOR lncRNA H2O2 glaucoma RGCs H2O2 treatment ?The expression of THOR was reduced in H2O2-induced RGCs. 33811613 827 Mouse THRIL lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) lung tissues lipopolysaccharide (LPS) treatment THRIL was highly expressed in the lung of sepsis mice. 32818819 828 Mouse THRIL lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) ATDC5 cells lipopolysaccharide (LPS) treatment LPS significantly induced ATDC5 cell inflammatory injury and upregulated the expression of THRIL. 30521964 829 Mouse THRIL lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) ATDC5 cells lipopolysaccharide (LPS) treatment LPS significantly induced ATDC5 cell inflammatory injury and upregulated the expression of THRIL. 30521964 830 Mouse TINCR lncRNA Tri-DAP inflammation 3T3-L1 adipocytes Tri-DAP treatment upregulated 30851423 831 Mouse Tnfaip3 lncRNA lipopolysaccharide (LPS) inflammation RAW264.7 mouse macrophage cells lipopolysaccharide (LPS) treatment upregulated 27979905 832 Mouse TSIX lncRNA Co-Cr-Mo metal particles (CoPs) particle-induced osteolysis (PIO) MC3T3-E1 cells Co-Cr-Mo metal particles (CoPs) treatment upregulated 29260905 833 Mouse Ttc3-209 lncRNA hank's balanced salt solution containing 10 ?M antimycin A retinal ischemia reperfusion injury (RIR) primary mouse retinal ganglion cells Hank's balanced salt solution containing 10 ?M antimycin A treatment lncRNA Ttc3-209 was significantly upregulated after I/R injury and played a proapoptotic role in RGCs during I/R-induced apoptosis. 33687475 834 Mouse TUG1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) Mouse cardiomyocytes HL-1 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment The expression of TUG1 was significantly upregulated in OGD/R-induced myocardial HL-1 cells The overexpression of TUG1-induced inflammation and apoptosis in OGD-R-induced myocardial HL-1 cells Knock down of TUG1 protected OGD/R-induced myocardial I/R injury by inhibiting HMGB1 expression Suppression of lncRNA TUG1 may prevent myocardial I/R injury following acute myocardial infarction via inhibiting HMGB1 expression 31432688 835 Mouse TUG1 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) lung tissues; primary murine pulmonary microvascular endothelial cells (PMVECs) lipopolysaccharide (LPS) treatment downregulated 32087725 836 Mouse TUG1 lncRNA H2O2 acute myocardial infarction (AMI) primary cultured cardiomyocytes H2O2 treatment upregulated 31145943 837 Mouse TUG1 lncRNA H2O2 acute myocardial infarction (AMI) primary cardiomyocytes H2O2 treatment LncRNA TUG1 mediates ischemic myocardial injury by targeting miR-132-3p/HDAC3 axis. 31858814 838 Mouse TUG1 lncRNA H2O2 acute myocardial infarction (AMI) mouse primary cardiomyocytes hydrogen peroxide (H2O2) treatment "miR-132-3p was downregulated, whereas TUG1 upregulated in H2O2-challenged cardiomyocytes." 31858814 839 Mouse TUG1 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) RAW 264.7 cells lipopolysaccharide (LPS) treatment LncRNA TUG1 reverses LPS-induced cell apoptosis and inflammation of macrophage via targeting MiR-221-3p/SPRED2 axis 32841583 840 Mouse TUG1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) hippocampal neurons amyloid-¦Â (A¦Â) 25-35 treatment TUG1 knockdown restricts apoptosis of hippocampal neurons in AD by elevating miR-15a and suppressing ROCK1 expression. 32577774 841 Mouse TUG1 lncRNA ovalbumin (OVA) asthma lung tissues ovalbumin (OVA) treatment upregulated 33640857 842 Mouse TUG1 lncRNA high fat diet (HFD) atherosclerosis (AS) aortas high fat diet (HFD) feed upregulated 29268138 843 Mouse TUG1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) RAW264.7 cells; MOVAS cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29268138 844 Mouse TUG1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) RAW264.7 and MOVAS cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29268138 845 Mouse TUG1 lncRNA hyperoxia bronchopulmonary dysplasia (BPD) MLE-12 cells hyperoxia treatment downregulated 33194901 846 Mouse TUG1 lncRNA hypoxia cardiac fibroblast-myofibroblast transformation (FMT) heart tissues hypoxia treatment upregulated 30066872 847 Mouse TUG1 lncRNA high glucose (HG) cardiac hypertrophy HL-1 cells high glucose (HG) treatment upregulated 32269707 848 Mouse TUG1 lncRNA phenylephrine (PE) cardiac hypertrophy cardiomyocytes; cardiac fibroblasts phenylephrine (PE) treatment LncRNA TUG1 alleviates cardiac hypertrophy by targeting miR©\34a/DKK1/Wnt©\¦Â©\catenin signalling 32057178 849 Mouse TUG1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury MA-C cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment LncRNA TUG1 expression was significantly upregulated in cultured MA-C cells exposed to OGD/R injury 31709761 850 Mouse TUG1 lncRNA astragaloside IV (AS-IV) diabetic nephropathy (DN) MPC5 cells astragaloside (AS-IV) treatment "TUG1 was downregulated and TRAF5 was upregulated in high-glucose-treated MPC5 cells, and AS-IV ameliorated the TUG1 level." 30233141 851 Mouse TUG1 lncRNA high glucose (HG) dysfunction of endothelial progenitor cells (EPCs) EPCs high glucose (HG) treatment TUG1 restores high glucose-treated EPC function by regulating miR-29c-3p/PDGF-BB/Wnt signaling. 33059750 852 Mouse TUG1 lncRNA chlorogenic acid (CGA) glaucoma retinal tissues Chlorogenic acid (CGA) treatment "IPL thickness and lncRNA TUG1 expression were significantly decreased in glaucoma mice model, and CGA treatment increased IPL thickness and lncRNA TUG1 expression." 31055996 853 Mouse TUG1 lncRNA chlorogenic acid (CGA) glaucoma mouse retinal ganglion cell (RGC) Chlorogenic acid (CGA) treatment "IPL thickness and lncRNA TUG1 expression were significantly decreased in glaucoma mice model, and CGA treatment increased IPL thickness and lncRNA TUG1 expression." 31055996 854 Mouse TUG1 lncRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) Mouse hepatic cell line AML12 hypoxia induce upregulated 31297532 855 Mouse TUG1 lncRNA propofol (PPF) hepatic ischemia/reperfusion injury (HIRI) Mouse hepatic cell Propofol induce treatment Propofol increases cell viability and lncRNA-TUG1 expression level in H/R-treated hepatic cells 31297532 856 Mouse TUG1 lncRNA lipopolysaccharide (LPS) inflammation The mouse immortalized podocyte cell line MPC5 lipopolysaccharide (LPS) treatment downregulated 31115515 857 Mouse TUG1 lncRNA tumor necrosis factor alpha (TNF-¦Á) irritable bowel syndrome (IBS) mouse interstitial cells of Cajal (ICC) tumor necrosis factor alpha (TNF-¦Á) treatment TUG1 was downregulated in TNF-¦Á-treated ICC. 30657572 858 Mouse TUG1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemia/reperfusion (I/R) injury MA-C cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment LncRNA TUG1 expression was significantly upregulated in cultured MA-C cells exposed to OGD/R injury 31709761 859 Mouse TUG1 lncRNA cold liver damage livers cold treatment downregulated 26785829 860 Mouse TUG1 lncRNA carbon tetrachloride (CCl4) liver fibrosis liver tissues; primary mouse HSCs carbon tetrachloride (CCl4) treatment Tug1 expression was significantly upregulated in fibrotic livers. 29904430 861 Mouse TUG1 lncRNA TGF-¦Â liver fibrosis primary mouse HSCs TGF-¦Â treatment upregulated 29904430 862 Mouse TUG1 lncRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) cardiomyocytes hypoxia/reoxygenation (H/R) treatment The expression of TUG1 was significantly increased in the I/R cardiomyocyte injury models. 33164260 863 Mouse TUG1 lncRNA oxygen glucose deprivation (OGD) neuroinflammation BV-2 microglial cells oxygen-glucose deprivation (OGD) induce treatment upregulated 31551710 864 Mouse TUG1 lncRNA high glucose (HG) obesity 3T3-L1 cells high glucose treatment LncRNA TUG1 could negatively regulate miR-204 to alleviate inflammation and insulin tolerance via promoting SIRT1/GLUT4/PPAR¦Ã/AKT pathway. 32888158 865 Mouse TUG1 lncRNA emodin osteoarthritis (OA) ATDC5 cells emodin treatment TUG1 was upregulated by emodin. 29710506 866 Mouse TUG1 lncRNA oxygen pathological neovascularization mouse ocular neovascularization exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment dysregulated 24623407 867 Mouse TUG1 lncRNA pyrrolidinedithiocarbamic acid (PDTC) pristine-induced systemic lupus erythematosus (SLE) kidney tissues pyrrolidine dithiocarbamate (PDTC) treatment NF-¦ÊB inhibition with PDTC protected against the kidney injury of pristine-induced SLE mice possibly via up-regulating lncRNA TUG1 31930775 868 Mouse TUG1 lncRNA hypoxia pulmonary arterial hypertension (PAH) pulmonary arteries tissues hypoxia induce upregulated 31679623 869 Mouse TUG1 lncRNA dextran sodium sulfate (DSS) ulcerative colitis (UC) colon dextran sodium sulfate (DSS) treatment TUG1 inhibits IEC apoptosis and UC progression by regulating the balance of HuR and miR-29b-3p. 33047284 870 Mouse TUG1 lncRNA dextran sodium sulfate (DSS) ulcerative colitis (UC) colon tissues dextran sodium sulfate (DSS) treatment downregulated 33047284 871 Mouse TUG1 lncRNA tumor necrosis factor alpha (TNF-¦Á) ulcerative colitis (UC) YAMC cells tumor necrosis factor alpha (TNF-¦Á) treatment TUG1 inhibits IEC apoptosis and UC progression by regulating the balance of HuR and miR-29b-3p 33047284 872 Mouse TUG1 lncRNA tumor necrosis factor alpha (TNF-¦Á) ulcerative colitis (UC) murine colonic epithelial YAMC cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 33047284 873 Mouse TUG1 lncRNA oxygen glucose deprivation (OGD) vascular cognitive impairment (VCI) HT22 cells oxygen and glucose deprivation-induced treatment "knockdown of TUG1 reduced hippocampal neuronal apoptosis and participates in the aerobic exercise-alleviated VCI, which was partly through regulating BDNF" 33213523 874 Mouse TUG1 lncRNA lipopolysaccharide (LPS) hepatitis liver tissues lipopolysaccharide (LPS) treatment ?Microarray showed that lncRNA TUG1 was upregulated in LPS-induced hepatocyte inflammation. 33644034 875 Mouse Uc.173 lncRNA lead (Pb) nerve injury hippocampus lead treatment downregulated 26683706 876 Mouse uc.323 lncRNA phenylephrine (PE) cardiac hypertrophy Primary cultures of neonatal rat ventricular myocytes phenylephrine treatment downregulated 31735087 877 Mouse uc.333 lncRNA high fat diet (HFD) insulin resistance (IR) liver tissues high fat diet (HFD) feed downregulated 32303004 878 Mouse uc.333 lncRNA IL-6 insulin resistance (IR) liver tissues IL-6 treatment downregulated 32303004 879 Mouse uc.333 lncRNA tumor necrosis factor alpha (TNF-¦Á) insulin resistance (IR) liver tissues tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 32303004 880 Mouse uc.418 lncRNA high fat diet (HFD) insulin resistance (IR) liver tissues high fat diet (HFD) feed downregulated 32303004 881 Mouse uc.420 lncRNA high fat diet (HFD) insulin resistance (IR) liver tissues high fat diet (HFD) feed downregulated 32303004 882 Mouse uc.48+ lncRNA P2X3 receptor diabetic neuropathic pain (DNP) dorsal root ganglia serum treatment upregulated 26686228 883 Mouse uc.48+ lncRNA high glucose and free fatty acids (HG-FFA) type 2 diabetes mellitus (T2DM) RAW264.7 cells high glucose and high plasma free fatty acids (FFAs) treatment "It was found that treatment of RAW264.7 cells with high glucose and FFAs, which exhibited increased expression of uc.48+." 29750294 884 Mouse uc.77 lncRNA paraquat (PQ) idiopathic pulmonary fibrosis (IPF) alveolar epithelial cells paraquat (PQ) treatment upregulated 26824344 885 Mouse uc007coi.2 lncRNA cigarette smoke (CS) airway inflammation C57BL/6 mice lung tissue cigarette smoke (CS) exposure dysregulated 29383188 886 Mouse uc007dlv lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment decreased 25827714 887 Mouse uc007eib lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment upregulated 25827714 888 Mouse uc008hps.1 lncRNA fasciola gigantica excretory/secretory products (ESP) macrophage activation and polarization M2 macrophages fasciola gigantica excretory/secretory products (ESP) treatment upregulated 29794463 889 Mouse uc008pwj lncRNA peritoneal dialysis fluid (PDF) peritoneal fibrosis peritoneal tissues peritoneal dialysis fluid (PDF) treatment decreased 25827714 890 Mouse uc008tgd.1 lncRNA cigarette smoke (CS) airway inflammation C57BL/6 mice lung tissue cigarette smoke (CS) exposure dysregulated 29383188 891 Mouse uc009njr.1 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment uc009njr.1 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP). 29115403 892 Mouse uc009njr.1 lncRNA cyclic adenosine monophosphate (cAMP) gluconeogenesis primary mouse hepatocytes cyclic adenosine monophosphate (cAMP) treatment downregulated 29115403 893 Mouse uc009njr.1 lncRNA metformin (Met) gluconeogenesis primary mouse hepatocytes metformin (Met) treatment uc009njr.1 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group. 29115403 894 Mouse uc011wph.1 lncRNA cigarette smoke (CS) airway inflammation C57BL/6 mice lung tissue cigarette smoke (CS) exposure dysregulated 29383188 895 Mouse UCA1 lncRNA phenylephrine (PE) cardiac hypertrophy cardiomyocytes phenylephrine (PE) treatment lncRNA UCA1 was highly expressed in the cardiomyocytes treated with phenylephrine (PE) 29616999 896 Mouse UCA1 lncRNA metformin (Met) endometrial hyperplasia (EH) endometrial hyperplasia (EH) mice uterus metformin (Met) treatment downregulated 31894313 897 Mouse UCA1 lncRNA tamoxifen (TAM) endometrial hyperplasia (EH) uterus tamoxifen treatment upregulated 31894313 898 Mouse UCA1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 30536337 899 Mouse UCA1 lncRNA kainic acid (KA) temporal lobe epilepsy (TLE) hippocampal tissues kainic acid (KA) treatment UCA1 was overexpressed in mice and the overexpression of UCA1 significantly reversed the abnormal proliferation of hippocampal neurons in epilepsy mice. 33829718 900 Mouse Vax2os1 lncRNA oxygen pathological neovascularization mouse ocular neovascularization exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment dysregulated 24623407 901 Mouse Wfdc21 lncRNA lipopolysaccharide (LPS) sepsis RAW264.7 cells lipopolysaccharide (LPS) treatment Wfdc21 level was elevated in LPS-treated RAW264.7 cells. 29900929 902 Mouse XIST lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Mouse podocytes (MPC5) MPC5 were treated with 100 ng/mL LPS (Sigma-Aldrich) for 48 h lncRNA XIST was significantly upregulated in LPS-treated MPCs. 31658856 903 Mouse XIST lncRNA H2O2 Alzheimer's disease (AD) N2a cells Hydrogen peroxide (H2O2 ) treatment The expression of lncRNA XIST was significantly upregulated in H2O2-treated N2a cells. 31743528 904 Mouse XIST lncRNA oxygen bronchopulmonary dysplasia (BPD) lung tissues oxygen treatment silencing of Xist suppressed BPD development by binding to miR-101-3p and downregulating HMGB3 and the TGF-b1/Smad3 axis. 33070148 905 Mouse XIST lncRNA phenylephrine (PE) cardiac hypertrophy cardiomyocytes phenylephrine (PE) treatment (XIST) was upregulated in hypertrophic cardiac of mice and phenylephrine (PE)-treated cardiomyocytes 30297107 906 Mouse XIST lncRNA lipopolysaccharide (LPS) cardiomyocytes injury Mouse cardiomyocytes MCM cells lipopolysaccharide (LPS) treatment The level of xist in the myocardial cells was markedly higher in the LPS group compared with the control group. 33029099 907 Mouse XIST lncRNA IL-1¦Â chondrocyte apoptosis ATDC5 IL-1¦Â treatment downregulated 32517436 908 Mouse XIST lncRNA streptozocin (STZ) diabetic nephropathy (DN) mouse renal tissues streptozotocin (STZ) treatment silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN 31545928 909 Mouse XIST lncRNA lipopolysaccharide (LPS) inflammation J774A.1 (mouse macrophage cell line) lipopolysaccharides (LPS) treatment upregulated 29773953 910 Mouse XIST lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) mouse neuronal cells oxygen-glucose deprivation (OGD) treatment upregulated 33738662 911 Mouse XIST lncRNA lipopolysaccharide (LPS) membranous nephropathy (MN) mouse podocyte cell line with lipopolysaccharides treatment upregulated 25157805 912 Mouse XIST lncRNA hypoxia myocardial infarction (MI) neonatal mice cardiomyocytes (NMCMs) hypoxia treatment XIST was upregulated in NMCMs under anoxia condition. 32315985 913 Mouse XIST lncRNA hypoxia myocardial ischemia/reperfusion (I/R) injury (MIRI) I/R mice myocardial tissues The myocardial I/R injury was induced by temporary ligation of the left anterior descending coronary artery. upregulated 31734557 914 Mouse XIST lncRNA hypoxia postmyocardial infarction AC16 cells hypoxia treatment "XIST and PDE4D were overexpressed in post-MI myocardial cells, whereas miR-130a-3p was underexpressed in post-MI myocardial cells." 29226319 915 Mouse XIST lncRNA bilateral common carotid artery occlusion (2-VO) Alzheimer's disease (AD) hippocampus tissues of AD mouse bilateral common carotid artery?occlusion (2VO) induce The expression of lncRNA XIST was significantly upregulated in 2VO-induced AD mice models 31743528 916 Mouse XIST lncRNA H2O2 Alzheimer's disease (AD) N2a mouse neuroblastoma cells Hydrogen peroxide (H2O2)?treatment The expression of lncRNA XIST was significantly upregulated in H2O2-treated N2a cells 31743528 917 Mouse XLOC_015129 lncRNA high fat diet (HFD) cholesterol biosynthesis liver tissues high fat diet (HFD) feed upregulated 30504232 918 Mouse XLOC_015129 lncRNA palmitic acid (PA) cholesterol biosynthesis AML12 cells palmitic acid (PA) treatment upregulated 30504232 919 Mouse XLOC_015129 lncRNA WY14643 cholesterol biosynthesis AML12 cells WY14643 treatment upregulated 30504232 920 Mouse XLOC_032768 lncRNA cisplatin (DDP) cisplatin (DDP)-induced nephrotoxicity renal tubular epithelial cells cisplatin treatment lncRNA XLOC_032768 expression was significantly repressed by cisplatin treatment. 32278129 921 Mouse XR_006756 lncRNA subarachnoid hemorrhage (SAH) early brain injury (EBI) brain subarachnoid hemorrhage (SAH) treatment downregulated 25777551 922 Mouse XR_140468 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) placenta high fat diet (HFD) feed downregulated 29986645 923 Mouse XR_141088 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed downregulated 29986645 924 Mouse XR_141492 lncRNA high fat diet (HFD) gestational diabetes mellitus (GDM) gonadal fat tissues high fat diet (HFD) feed downregulated 29986645 925 Mouse ZEB2-AS1 lncRNA phenylephrine (PE) cardiac hypertrophy primary cardiomyocytes phenylephrine (PE) treatment lncRNA ZEB2-AS1 may influence the progression of CH by downregulating PTEN 32973941 926 Mouse ZFAS1 lncRNA hypoxia/reoxygenation (H/R) acute myocardial infarction (AMI) HL-1 Cells hypoxia/reoxygenation (H/R) treatment ZFAS1 was upregulated and miR-761 was downregulated in the serum of patients with AMI and H/R-induced HL-1 cells. 32833901 927 Mouse ZFAS1 lncRNA lipopolysaccharide (LPS) spinal cord injury (SCI) BV2 cells lipopolysaccharide (LPS) treatment ?ZFAS1 was identified to be upregulated in spinal cord tissues of SCI mice. 33524472 928 Mouse ZFAS1 lncRNA high fat diet (HFD) atherosclerosis (AS) ApoE-/- mice heart tissues high fat diet (HFD) feed We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs. 33278458 929 Mouse ZNF593-AS lncRNA phenylephrine (PE) dilated cardiomyopathy (DCM) cardiomyocytes phenylephrine treatment "ZNF593-AS, which mainly localized in the cytoplasm of cardiomyocytes, was robustly decreased in the failing heart of DCM patients, as well as in phenylephrine-treated human cardiomyocytes" 33550812